1
|
Mita K, Izumi K, Goriki A, Tasaka R, Hatayama T, Shima T, Kato Y, Kamiyama M, Inoue S, Tanaka N, Hoshi S, Okamura T, Yoshio Y, Enokida H, Chikazawa I, Kawai N, Hashimoto K, Fukagai T, Shigehara K, Takahara S, Kadono Y, Mizokami A. Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa. Cancers (Basel) 2024; 16:508. [PMID: 38339260 PMCID: PMC10854983 DOI: 10.3390/cancers16030508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2023] [Revised: 01/07/2024] [Accepted: 01/20/2024] [Indexed: 02/12/2024] Open
Abstract
Enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) can improve the survival of patients with castration-resistant prostate cancer (CRPC). However, the agent that is more effective against nonmetastatic CRPC remains unclear. To evaluate the agent that can be used as the first-line treatment for CRPC, an investigator-initiated, multicenter, randomized controlled trial (ENABLE Study for PCa) including both metastatic and nonmetastatic CRPC was conducted in Japan. The prostate-specific antigen (PSA) response rate, overall survival, some essential survival endpoints, and safety of patients with nonmetastatic CRPC were also analyzed. In this subanalysis, 15 and 26 patients in the ENZ and ABI arms, respectively, presented with nonmetastatic CRPC. There was no significant difference in terms of the PSA response rate between the ENZ and ABI arms (80% and 64%, respectively; p = 0.3048). The overall survival did not significantly differ between the two arms (HR: 0.68; 95% CI: 0.22-2.14, p = 0.5260). No significant differences were observed in terms of radiographic progression-free survival and cancer-specific survival between the ENZ and ABI arms (HR: 0.81; 95% CI: 0.35-1.84; p = 0.6056 and HR: 0.72; 95% CI: 0.19-2.73; p = 0.6443, respectively). Only four and six patients in the ENZ and ABI arms, respectively, had ≥grade 3 adverse events. ABI and ENZ had similar efficacy and safety profiles in patients with nonmetastatic CRPC.
Collapse
Affiliation(s)
- Koji Mita
- Department of Urology, Hiroshima City North Medical Center Asa Citizens Hospital, 1-2-1 Kameyama-Minami, Asakita-ku, Hiroshima 731-0293, Japan
| | - Kouji Izumi
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa 920-8641, Japan
| | - Akihiro Goriki
- Department of Urology, Hiroshima City North Medical Center Asa Citizens Hospital, 1-2-1 Kameyama-Minami, Asakita-ku, Hiroshima 731-0293, Japan
- Department of Urology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan
| | - Ryo Tasaka
- Department of Urology, Hiroshima City North Medical Center Asa Citizens Hospital, 1-2-1 Kameyama-Minami, Asakita-ku, Hiroshima 731-0293, Japan
- Department of Urology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan
| | - Tomoya Hatayama
- Department of Urology, Hiroshima City North Medical Center Asa Citizens Hospital, 1-2-1 Kameyama-Minami, Asakita-ku, Hiroshima 731-0293, Japan
- Department of Urology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan
| | - Takashi Shima
- Department of Urology, Toyama Prefectural Central Hospital, 2-2-78 Nishinagae, Toyama 930-8550, Japan
| | - Yuki Kato
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa 920-8641, Japan
- Department of Urology, Fukui-Ken Saiseikai Hospital, 7-1 Wadanakacho-Funabashi, Fukui 918-8503, Japan
| | - Manabu Kamiyama
- Department of Urology, University of Yamanashi, 1110 Shimokato, Chuo 409-3898, Japan
| | - Shogo Inoue
- Department of Urology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan
- Department of Urology, Shobara Red Cross Hospital, 2-7-10 Nishihonmachi, Shobara 727-0013, Japan
| | - Nobumichi Tanaka
- Department of Urology, Nara Medical University, 840 Shijocho, Kashihara 634-8521, Japan
| | - Seiji Hoshi
- Department of Urology, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan
| | - Takehiko Okamura
- Department of Urology, Anjo Kosei Hospital, 28 Anjocho-Higashihirokute, Anjo 446-8602, Japan
| | - Yuko Yoshio
- Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu 514-8507, Japan
| | - Hideki Enokida
- Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan
| | - Ippei Chikazawa
- Department of Urology, Kanazawa Medical University, 1-1 Uchinadamachi-Daigaku, Kahoku 920-0293, Japan
| | - Noriyasu Kawai
- Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8602, Japan
| | - Kohei Hashimoto
- Department of Urology, School of Medicine, Sapporo Medical University, 16-291 Minami-1-Jo-Nishi, Sapporo 060-8543, Japan
| | - Takashi Fukagai
- Department of Urology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan
| | - Kazuyoshi Shigehara
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa 920-8641, Japan
- Department of Urology, Ishikawa Prefectural Central Hospital, 2-1 Kuratsukihigashi, Kanazawa 920-8530, Japan
| | - Shizuko Takahara
- Innovative Clinical Research Center, Kanazawa University, 13-1 Takaramachi, Kanazawa 920-8641, Japan
- Medical Research Support Center, University of Fukui Hospital, 23-3 Shimoaizuki, Matsuoka Eiheiji-cho Yoshida-gun, Fukui 910-1193, Japan
| | - Yoshifumi Kadono
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa 920-8641, Japan
| | - Atsushi Mizokami
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa 920-8641, Japan
| |
Collapse
|
2
|
Ihara T, Shinozaki Y, Shigetomi E, Danjo Y, Tsuchiya S, Kanda M, Kamiyama M, Takeda M, Koizumi S, Mitsui T. G protein-coupled receptor 55 activated by palmitoylethanolamide is associated with the development of nocturia associated with circadian rhythm disorders. Life Sci 2023; 332:122072. [PMID: 37704067 DOI: 10.1016/j.lfs.2023.122072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2023] [Revised: 08/17/2023] [Accepted: 09/03/2023] [Indexed: 09/15/2023]
Abstract
AIMS Bladder function is regulated by clock genes and dysregulation of circadian bladder function can cause nocturia. The blood concentration of palmitoylethanolamide (PEA), a fatty acid metabolite, changes with circadian rhythm. Clock gene abnormalities demonstrate the highest PEA levels during the sleep phase. PEA is a GPR55 agonist that influences urination; therefore, increased PEA during the sleep phase may cause nocturia. Herein, we investigated the function of GPR55 to evaluate the relationship between GPR55 and nocturia that evoked higher PEA during the sleep phase in patients with circadian rhythm disorders. MAIN METHODS Male C57BL/6 mice were used. GPR55 localization was evaluated by immunofluorescence staining, qRT-PCR, and western blotting. Variations in PEA-induced intracellular Ca2+ concentrations were measured in primary cultured mouse urothelial cells (UCs) using Ca2+ imaging. PEA-induced NGF and PGI2 release in UCs was measured by ELISA. The micturition reflex pathway after PEA administration was evaluated using immunofluorescence staining. KEY FINDINGS GPR55 was predominant in the UC layer. PEA induced release of Ca2+ from the endoplasmic reticulum into the UC cytoplasm. ELISA and immunofluorescence staining revealed that NGF and PGI2 were released from bladder UCs, stimulated the pontine micturition center in mice, and induced nocturia. SIGNIFICANCE The loss of regular circadian metabolizing rhythm in fatty acids causes higher blood PEA levels during the sleep phase. Binding of PEA to GPR55 in UC may activate the downstream processes of the micturition reflex, leading to nocturia. These findings suggest a new mechanism for nocturia and its potential as a therapeutic target.
Collapse
Affiliation(s)
- Tatsuya Ihara
- Department of Urology, Toranomon Hospital Kajigaya, Kawasaki, Kanagawa 213-8587, Japan.
| | - Youichi Shinozaki
- Visual Research Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan
| | - Eiji Shigetomi
- Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan
| | - Yosuke Danjo
- Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan
| | - Sachiko Tsuchiya
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan
| | - Mie Kanda
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan
| | - Manabu Kamiyama
- Department of Urology, Toranomon Hospital Kajigaya, Kawasaki, Kanagawa 213-8587, Japan
| | - Masayuki Takeda
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan
| | - Schuichi Koizumi
- Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan
| | - Takahiko Mitsui
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan
| |
Collapse
|
3
|
Koshiro N, Nakajima K, Oyama M, Kaneko G, Takahashi S, Matsuyama H, Shiina H, Ichikawa T, Horikoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A, Mizokami A. Predictive factors for the effectiveness of novel androgen receptor axis-targeted agents in patients with metastatic prostate cancer. Int J Urol 2022; 29:1477-1487. [PMID: 36070138 DOI: 10.1111/iju.15022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2022] [Accepted: 07/28/2022] [Indexed: 11/29/2022]
Abstract
OBJECTIVE Novel androgen receptor axis-targeted agents (ARATAs) have been developed for mCRPC and improved overall survival (OS). Here, we aimed to find predictors who will receive the greatest benefits from ARATAs. METHODS We previously performed a multicenter study to identify prognostic factors for metastatic hormone-sensitive prostate cancer (mHSPC, n = 148) and mCRPC (n = 99), and showed that the bone scan index (BSI) was one of the significant prognostic factors for 3-year OS (PROSTAT-BSI study). mHSPC progressed to mCRPC (n = 101), for which 69 patients were treated with (n = 39) or without ARATAs (n = 30, prior to the approval of ARATAs). The 69 patients were divided into two groups according to patient factors, and these cohorts were further divided into two subgroups by usage of ARATAs. OS was compared between subgroups in each group. RESULTS The predictors were age (<71.4 years), serum levels of C-reactive protein (≥0.16 ng/ml) and alkaline phosphatase (≥548 U/L), time to PSA progression after ADT (<8.9 months), the lowest PSA level (≥1 ng/ml) after ADT, and the rate of PSA decline 3 months after ADT (<0.987), whereas hemoglobin levels, PSA before ADT, Gleason scores, existence of visceral metastases, and BSI were not. CONCLUSIONS The present study identified predictors for the effectiveness of ARATAs. The number of bone metastases (≒BSI), existence of visceral metastases, and Gleason scores, which were identified as high-risk factors in the LATITUDE study and disease volume in CHAARTED criteria, did not appear to be useful for predicting effectiveness from ARATAs.
Collapse
Affiliation(s)
- Nishimoto Koshiro
- Department of Uro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan
| | - Kenichi Nakajima
- Department of Functional Imaging and Artificial Intelligence, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
| | - Masafumi Oyama
- Department of Uro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan
| | - Go Kaneko
- Department of Uro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan
| | - Satoru Takahashi
- Department of Urology, Nihon University School of Medicine, Tokyo, Japan
| | - Hideyasu Matsuyama
- Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Japan
| | - Hiroaki Shiina
- Department of Urology, Shimane University Faculty of Medicine, Shimane, Japan
| | - Tomohiko Ichikawa
- Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Hiroyuki Horikoshi
- Department of Diagnostic Radiology, Gunma Prefectural Cancer Center, Ota, Japan
| | - Katsuyoshi Hashine
- Department of Urology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - Yutaka Sugiyama
- Department of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
| | - Takeshi Miyao
- Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Manabu Kamiyama
- Department of Urology, University of Yamanashi, Yamanashi, Japan
| | - Kenichi Harada
- Division of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Akito Ito
- Department of Urology, Iwate Medical University, Iwate, Japan
| | - Atsushi Mizokami
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
| | | |
Collapse
|
4
|
Kamijima T, Yaegashi H, Mizokami A, Nakajima K, Matsuyama H, Ichikawa T, Nishimoto K, Takahashi S, Shiina H, Horikoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A, Enokida H. Efficacy of Androgen Receptor-targeted Drugs After Prostate Cancer Recurrence With Bone Metastases: PROSTAT-BSI Sub-analysis. Anticancer Res 2022; 42:3099-3108. [PMID: 35641302 DOI: 10.21873/anticanres.15798] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2022] [Revised: 05/13/2022] [Accepted: 05/16/2022] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM This study aimed to evaluate the therapeutic benefit of novel androgen receptor-targeted agents (ARTAs) in castration-resistant prostate cancer (CRPC) with bone metastases in Japan. PATIENTS AND METHODS In followup to our prospective observational study (PROSTAT-BSI) from 2012 to 2018 on metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic CRPC (mCRPC) before docetaxel initiation, we conducted this sub-analysis to investigate the benefit of ARTAs after clinical recurrence on overall survival (OS) in the real-world clinical setting in Japan. In this study, we compared patients who were treated with ARTA with those who received only vintage hormone therapy including docetaxel after clinical recurrence. RESULTS In the mHSPC group, 69 patients became mCRPC and were treated with or without ARTAs. No significant difference was observed in prostate-specific antigen (PSA) progression-free survival between the ARTA (+) and ARTA (-) groups; however, OS after clinical recurrence was significantly better in the ARTA (+) group than in the ARTA (-) group (median OS 31.9 vs. 23.0 months; p<0.01). CONCLUSION The ARTAs are beneficial even after mHSPC recurrence in Japanese patients in the real-world clinical setting. Since ARTAs are beneficial after clinical recurrence, it may be better to switch to ARTAs whenever necessary based on PSA response after combined androgen blockade therapy, considering the adverse effects and cost. This approach may be suitable to reduce overtreatment in Japanese patients with mHSPC.
Collapse
Affiliation(s)
- Taiki Kamijima
- department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
| | - Hiroshi Yaegashi
- department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
| | - Atsushi Mizokami
- department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
| | - Kenichi Nakajima
- Department of Functional Imaging and Artificial Intelligence, Kanazawa University, Kanazawa, Japan
| | - Hideyasu Matsuyama
- Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Japan
| | - Tomohiko Ichikawa
- Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Koshiro Nishimoto
- Department of Uro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan
| | - Satoru Takahashi
- Department of Urology, Nihon University School of Medicine, Tokyo, Japan
| | - Hiroaki Shiina
- Department of Urology, Shimane University Faculty of Medicine, Shimane, Japan
| | - Hiroyuki Horikoshi
- Department of Diagnostic Radiology, Gunma Prefectural Cancer Center, Ota, Japan
| | - Katsuyoshi Hashine
- Department of Urology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - Yutaka Sugiyama
- Department of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
| | - Takeshi Miyao
- Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Manabu Kamiyama
- Department of Urology, University of Yamanashi, Yamanashi, Japan
| | - Kenichi Harada
- Division of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Akito Ito
- Department of Urology, Iwate Medical University, Yahaba, Japan
| | - Hideki Enokida
- Department of Urology, Kagoshima University, Kagoshima, Japan
| |
Collapse
|
5
|
Miki K, Nakamura Y, Yokoyama T, Kamiyama M, Ishii Y. Therapeutic Effect of Roxadustat on Patients With Posttransplant Anemia. Transplant Proc 2022; 54:671-677. [DOI: 10.1016/j.transproceed.2022.02.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Accepted: 02/01/2022] [Indexed: 10/18/2022]
|
6
|
Mizokami A, Nishimoto K, Matsuyama H, Ichikawa T, Takahashi S, Shiina H, Hashine K, Sugiyama Y, Kamiyama M, Enokida H, Nakajima K. Efficacy of New Therapies for Relapse After Docetaxel Treatment of Bone Metastatic Castration-resistant Prostate Cancer in Clinical Practice. Anticancer Res 2022; 42:1465-1475. [PMID: 35220240 DOI: 10.21873/anticanres.15617] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2021] [Revised: 01/13/2022] [Accepted: 12/14/2022] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM To assess the efficacy of novel therapeutic agents, such as androgen receptor axis-targeted agents (ARATs) and cabazitaxel, for relapse of metastatic castration-resistant prostate cancer (mCRPC) after docetaxel in real-world practice, we performed a subanalysis using database from PROSTAT-BSI, a prospective observational study to evaluate the utility of software for quantifying bone metastases on bone scintigraphy. PATIENTS AND METHODS Patients with clinically relapsed mCRPC after docetaxel treatment who received the new agents (NEW group) and those who did not (standard of care, SOC group) were included; patients who received ARAT before DOC treatment were excluded. Overall survival (OS) after docetaxel treatment was compared between the NEW and SOC groups. RESULTS Patients in the NEW group had significantly better OS from the start of docetaxel than those in the SOC group (the median OS in NEW and SOC was 28.9 months vs. 14.5 months, respectively). Furthermore, regardless of the time from androgen-deprivation therapy to the start of docetaxel at mCRPC, the NEW group had a better OS from relapse after docetaxel than the SOC group. CONCLUSION In clinical practice, OS of patients with relapse after docetaxel was significantly improved in the NEW group over the SOC group.
Collapse
Affiliation(s)
- Atsushi Mizokami
- Kanazawa University Graduate School of Medical Science, Ishikawa, Japan;
| | - Koshiro Nishimoto
- International Medical Center, Saitama Medical University, Hidaka, Japan
| | - Hideyasu Matsuyama
- Department of Urology, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan
| | - Tomohiko Ichikawa
- Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Satoru Takahashi
- Department of Urology, Nihon University School of Medicine, Tokyo, Japan
| | - Hiroaki Shiina
- Department of Urology, Shimane University Faculty of Medicine, Matsue, Japan
| | | | - Yutaka Sugiyama
- Department of Urology, Kumamoto University Faculty of Life Sciences, Kumamoto, Japan
| | - Manabu Kamiyama
- Department of Urology, Yamanashi University School of Medicine, Yamanashi, Japan
| | - Hideki Enokida
- Department of Urology, Kagoshima University Faculty of Medicine, Kagoshima, Japan
| | - Kenichi Nakajima
- Department of Nuclear Medicine, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
| |
Collapse
|
7
|
Nishimoto K, Nakajima K, Oyama M, Kaneko G, Takahashi S, Matsuyama H, Shiina H, Ichikawa T, Horikoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A, Mizokami A. Predictive factors for effectiveness from novel androgen-receptor-axis-targeted agents in patients with metastatic prostate cancer. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.6_suppl.033] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
33 Background: About a half of men with prostate cancer progress to metastatic castration-resistant prostate cancer (mCRPC) one year after the initiation of androgen-deprivation therapy (ADT), whereas approximately 20 % of men keep the sensitivity to ADT more than 5 years. Several novel androgen-receptor-axis-targeted agents (ARATAs) were developed for the treatment of mCRPC, and improved overall survival (OS) in patients with mCRPC; however, to which patients these ARATAs were more beneficial is yet to be determined. We conducted this study to identify factors that predict effectiveness from ARATAs for mCRPC. Methods: We previously performed a multicenter study to determine prognostic factors including bone scan index (BSI) in patients with metastatic hormone sensitive prostate cancer (n = 148) and mCRPC (n = 99), which showed that BSI was one of the significant determinants of 3-year OS (PROSTAT-BSI study). The patients with mHSPC progressed to mCRPC (n = 101). Among these mCRPC patients, 69 patients received treatments with or without ARATAs, because the patients were recruited before and after approval of ARATAs in Japan. We used the data of the 69 patients to identify predictors for effective use of ARTA. The cohort was divided into two groups according to patient factors by several thresholds, and these two cohorts were further divided into two subgroups: those who received and did not receive ARATAs (abiraterone or enzalutamide). OS was compared between these two cohort groups to evaluate contribution of each factor. Categorical values were analyzed in the same way, although no threshold setting was required. Results: Factors, in which the significant treatment effect from ARATAs was observed between subgroups in only one group (eg. age < 71.4 vs age ≥ 71.4), were age ( < 71.4 years); serum levels of C-reactive protein (≥0.16 ng/mL), alkaline phosphatase (≥548 U/L), and type 1 collagen C-terminal telopeptide ( < 6.4 ng/mL); time to PSA progression after ADT ( < 8.9 months); lowest PSA level (≥1 ng/mL) after ADT; and rate of PSA decline 3 month after ADT ( <.987). Whereas, no significant difference was observed between two groups in cohorts divided by hemoglobin level, PSA before ADT, Gleason score, and BSI. Conclusions: This study identified the predictors of the effectiveness from ARATAs. In addition, the number of bone metastases (corresponding to BSI) and Gleason score, which were considered as high-risk factors in the LATITUDE study and disease volume in the CHAARTED criteria, may not be useful for predicting the effectiveness from ARATAs.
Collapse
Affiliation(s)
- Koshiro Nishimoto
- International Medical Center, Saitama Medical University, Hidaka, Japan
| | - Kenichi Nakajima
- Department of Functional Imaging and Artificial Intelligence, Kanazawa University, Kanazawa, Japan
| | - Masafumi Oyama
- Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - Go Kaneko
- Saitama Medical University International Medical Center, Saitama, Japan
| | - Satoru Takahashi
- Department of Urology, Nihon University School of Medicine, Tokyo, Japan
| | - Hideyasu Matsuyama
- Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan
| | - Hiroaki Shiina
- Department of Urology, Shimane University Faculty of Medicine, Matsue, Japan
| | - Tomohiko Ichikawa
- Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Hiroyuki Horikoshi
- Department of Diagnostic Radiology, Gunma Prefectural Cancer Center, Ota, Japan
| | | | - Yutaka Sugiyama
- Department of Urology, Kumamoto University Faculty of Life Sciences, Kumamoto, Japan
| | | | - Manabu Kamiyama
- Department of Urology, Yamanashi University School of Medicine, Yamanashi, Japan
| | - Kenichi Harada
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Akito Ito
- Department of Urology, Iwate Medical University, Morioka, Morioka, Japan
| | - Atsushi Mizokami
- Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan
| | | |
Collapse
|
8
|
Izumi K, Shima T, Mita K, Kato Y, Kamiyama M, Inoue S, Tanaka N, Hoshi S, Okamura T, Yoshio Y, Enokida H, Chikazawa I, Kawai N, Hashimoto K, Fukagai T, Shigehara K, Takahara S, Kadono Y, Mizokami A. Enzalutamide versus abiraterone plus prednisolone before chemotherapy for Japanese castration-resistant prostate cancer patients: An investigator-initiated, multicenter, randomized controlled trial. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.6_suppl.122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
122 Background: Enzalutamide and abiraterone plus prednisolone demonstrated improvement of survival for castration-resistant prostate cancer (CRPC). However, it remains quite unclear which agent is better in terms of efficacy and safety for Asian patients. Methods: An investigator-initiated, multicenter, randomized controlled trial was conducted in Japan. CRPC patients before chemotherapy were randomly assigned to the enzalutamide or the abiraterone plus prednisolone arm (1:1). The primary endpoint is time to prostate-specific antigen (PSA) progression and secondary endpoints include PSA response rate (≥50% decline from baseline), overall survival, radiographic progression-free survival, and safety assessment. Results: Between February 20, 2015 and July 30, 2019, 203 patients were enrolled. After randomization, 92 in the enzalutamide and 92 in the abiraterone plus prednisolone arm were treated and analyzed. Time to PSA progression was not significantly different between arms (median 21.2 and 11.9 months in the enzalutamide and the abiraterone plus prednisolone arm, respectively; hazard ration 0.81, 95% CI 0.51-1.27, p = 0.1732). There was a significant difference in PSA response rate between arms (72% and 57% in the enzalutamide and the abiraterone plus prednisolone arm, respectively, p = 0.0425). There were no significant differences in overall and radiographic progression-free survival between arms (median 32.9 and 35.5months in the enzalutamide and the abiraterone plus prednisolone arm, respectively; hazard ration 1.17, 95% CI 0.72-1.88, p = 0.5290 and median 17.6 and 14.0 months in the enzalutamide and the abiraterone plus prednisolone arm, respectively; hazard ration 0.92, 95% CI 0.63-1.34, p = 0.6532). Grade ≥3 of adverse events were observed in 11% and 21% in the enzalutamide and the abiraterone plus prednisolone arm, respectively ( p = 0.1044). Conclusions: Enzalutamide did not show any survival benefits compared with abiraterone plus prednisolone but showed better PSA response rate with no significant differences of severe adverse event rate for Japanese CRPC patients. Our data suggest that antecedent use of enzalutamide to abiraterone plus prednisolone have potentially clinical benefits in Asian CRPC populations. Clinical trial information: UMIN000015529.
Collapse
Affiliation(s)
- Kouji Izumi
- Kanazawa University Hospital, Kanazawa, Japan
| | | | - Koji Mita
- Hiroshima City Asa Hospital, Hiroshima, Japan
| | - Yuki Kato
- Kanazawa University Hospital, Kanazawa, Japan
| | - Manabu Kamiyama
- Department of Urology, Yamanashi University School of Medicine, Yamanashi, Japan
| | | | | | - Seiji Hoshi
- Fukushima Medical University, Fukushima, Japan
| | | | - Yuko Yoshio
- Mie University Graduate School of Medicine, Tsu, Japan
| | | | | | - Noriyasu Kawai
- Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
| | - Kohei Hashimoto
- Sapporo Medical University School of Medicine, Sapporo, Japan
| | | | | | | | - Yoshifumi Kadono
- Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
| | - Atsushi Mizokami
- Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan
| |
Collapse
|
9
|
Nagumo Y, Onozawa M, Kojima T, Terada N, Shiota M, Mitsuzuka K, Yasumoto H, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Saito T, Yokomizo A, Kohei N, Tabata K, Takahashi A, Sugimoto M, Kitamura H, Kamoto T, Nishiyama H, Shimazui T, Inoue T, Goto T, Hashimoto Y, Tomida R, Sakurai T, Hashimoto K, Kawamura S, Teraoka S, Sakamoto S, Kimura T, Kamiyama M, Narita S, Tanaka N, Kato T, Kato M, Osawa T. Efficacy of combined androgen blockade therapy in patients with metastatic hormone‐sensitive prostate cancer stratified by tumor burden. Int J Urol 2022; 29:398-405. [DOI: 10.1111/iju.14793] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2021] [Accepted: 12/28/2021] [Indexed: 12/18/2022]
Affiliation(s)
- Yoshiyuki Nagumo
- Department of Urology University of Tsukuba Tsukuba IbarakiJapan
| | - Mizuki Onozawa
- Department of Urology International University of Health and Welfare Narita City, ChibaJapan
| | - Takahiro Kojima
- Department of Urology University of Tsukuba Tsukuba IbarakiJapan
| | - Naoki Terada
- Department of Urology Miyazaki University MiyazakiJapan
| | - Masaki Shiota
- Department of Urology Kyushu University FukuokaJapan
| | | | | | | | - Hideki Enokida
- Department of Urology Kagoshima University KagoshimaJapan
| | - Takayuki Sugiyama
- Department of Urology Hamamatsu University School of Medicine HamamatsuJapan
| | - Kentaro Kuroiwa
- Department of Urology Miyazaki Prefectural Miyazaki Hospital MiyazakiJapan
| | - Toshihiro Saito
- Department of Urology Niigata Cancer Center Hospital NiigataJapan
| | | | - Naoki Kohei
- Department of Urology Shizuoka General Hospital ShizuokaJapan
| | | | | | | | - Hiroshi Kitamura
- Department of Urology Faculty of Medicine University of Toyama Toyama Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Shiota M, Terada N, Kitamura H, Kojima T, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata K, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Inoue T, Sugimoto M, Mizowaki T, Kamoto T, Nishiyama H, Eto M. Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer. Cancer Sci 2021; 112:3616-3626. [PMID: 34145921 PMCID: PMC8409413 DOI: 10.1111/cas.15038] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2021] [Revised: 06/09/2021] [Accepted: 06/17/2021] [Indexed: 12/21/2022] Open
Abstract
The metastatic burden is a critical factor for decision-making in the treatment of metastatic hormone-sensitive prostate cancer (HSPC). This study aimed to develop and validate a novel risk model for survival in patients with de novo low- and high-burden metastatic HSPC. The retrospective observational study included men with de novo metastatic prostate cancer who were treated with primary androgen-deprivation therapy at 30 institutions across Japan between 2008 and 2017. We created a risk model for overall survival (OS) in the discovery cohort (n = 1449) stratified by the metastatic burden (low vs high) and validated its predictive ability in a separate cohort (n = 951). Based on multivariate analyses, lower hemoglobin levels, higher Gleason grades, and higher clinical T-stage were associated with poor OS in low-burden disease. Meanwhile, lower hemoglobin levels, higher Gleason grade group, liver metastasis, and higher extent of disease scores in bone were associated with poor OS in patients with high-burden disease. In the discovery and validation cohorts, the risk model using the aforementioned parameters exhibited excellent discriminatory ability for progression-free survival and OS. The predictive ability of this risk model was superior to that of previous risk models. Our novel metastatic burden-stratified risk model exhibited excellent predictive ability for OS, and it is expected to have several clinical uses, such as precise prognostic estimation.
Collapse
Affiliation(s)
| | - Naoki Terada
- Department of UrologyMiyazaki UniversityMiyazakiJapan
| | - Hiroshi Kitamura
- Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for ResearchUniversity of ToyamaToyamaJapan
| | - Takahiro Kojima
- Department of UrologyUniversity of Tsukuba HospitalTsukubaJapan
| | - Toshihiro Saito
- Department of UrologyNiigata Cancer Center HospitalNiigataJapan
| | | | - Naoki Kohei
- Department of UrologyShizuoka General HospitalShizuokaJapan
| | | | | | | | | | | | | | - Ryotaro Tomida
- Department of UrologyShikoku Cancer CenterMatsuyamaJapan
| | | | | | - Toru Shimazui
- Department of UrologyIbaraki Prefectural Central Hospital, Ibaraki Cancer CenterKasamaJapan
| | | | - Manabu Kamiyama
- Department of UrologyUniversity of Yamanashi HospitalChuoJapan
| | | | | | - Takuma Kato
- Department of UrologyKagawa UniversityKagawaJapan
| | | | | | | | - Masashi Kato
- Department of UrologyNagoya UniversityNagoyaJapan
| | - Takahiro Osawa
- Department of Renal and Genitourinary SurgeryHokkaido UniversitySapporoJapan
| | | | | | | | - Takayuki Sugiyama
- Department of UrologyHamamatsu University School of MedicineHamamatsuJapan
| | - Kentaro Kuroiwa
- Department of UrologyMiyazaki Prefectural Miyazaki HospitalMiyazakiJapan
| | - Takahiro Inoue
- Department of Nephro‐Urologic Surgery and AndrologyMie University Graduate School of MedicineTsuJapan
| | | | - Takashi Mizowaki
- Department of Radiation Oncology & Image‐applied TherapyKyoto UniversityKyotoJapan
| | | | | | | | | |
Collapse
|
11
|
Nakajima K, Mizokami A, Matsuyama H, Ichikawa T, Kaneko G, Takahashi S, Shiina H, Horikoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A. Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort study. Int J Urol 2021; 28:955-963. [PMID: 34148264 PMCID: PMC8453930 DOI: 10.1111/iju.14614] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2021] [Accepted: 05/09/2021] [Indexed: 11/28/2022]
Abstract
Objective To determine prognostic factors including the Bone Scan Index in prostate cancer patients receiving standard hormonal therapy and chemotherapy. Methods This multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index study involved 30 hospitals and enrolled 247 patients (age 71 ± 8 years) with metastatic hormone‐sensitive prostate cancer (n = 148) under hormone therapy and metastatic castration‐resistant prostate cancer (n = 99) under chemotherapy. The Bone Scan Index (%) was determined by whole‐body bone scintigraphy using 99mTc‐methylenediphosphonate. Patients were classified into tertiles and binary groups, and predictors of all‐cause death including Bone Scan Index, prostate‐specific antigen, and bone metabolic markers were determined using survival and proportional hazard analyses. Results During a mean follow‐up period of 716 ± 404 days, 81 (33%) of the patients died, and 3‐year mortality rates were 20% and 52% in the metastatic hormone‐sensitive prostate cancer and metastatic castration‐resistant prostate cancer groups, respectively. Survival analysis showed that a Bone Scan Index >3.5% was a significant determinant of death in the metastatic hormone‐sensitive prostate cancer group, whereas prostate‐specific antigen >55 ng/mL before chemotherapy was a determinant of prognosis in the metastatic castration‐resistant prostate cancer group. A Bone Scan Index >3.5% was also associated with a high incidence of prostate‐specific antigen progression in the metastatic hormone‐sensitive prostate cancer group. Patients with metastatic hormone‐sensitive prostate cancer and a better Bone Scan Index response (>45%) to treatment had lower mortality rates than those without such response. Conclusion The Bone Scan Index and hot spot number are significant determinants of 3‐year mortality, and combining the Bone Scan Index with prostate‐specific antigen should contribute to the management of prostate cancer patients with bone metastasis.
Collapse
Affiliation(s)
- Kenichi Nakajima
- Department of Functional Imaging and Artificial Intelligence, Kanazawa University, Kanazawa, Japan
| | - Atsushi Mizokami
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
| | - Hideyasu Matsuyama
- Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Japan
| | - Tomohiko Ichikawa
- Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Go Kaneko
- Department of Uro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan
| | - Satoru Takahashi
- Department of Urology, Nihon University School of Medicine, Tokyo, Japan
| | - Hiroaki Shiina
- Department of Urology, Shimane University Faculty of Medicine, Shimane, Japan
| | - Hiroyuki Horikoshi
- Department of Diagnostic Radiology, Gunma Prefectural Cancer Center, Ota, Japan
| | - Katsuyoshi Hashine
- Department of Urology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - Yutaka Sugiyama
- Department of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
| | - Takeshi Miyao
- Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Manabu Kamiyama
- Department of Urology, University of Yamanashi, Yamanashi, Japan
| | - Kenichi Harada
- Division of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Akito Ito
- Department of Urology, Iwate Medical University, Yahaba, Japan
| | | |
Collapse
|
12
|
Kobayashi M, Narita S, Matsui Y, Kanda S, Hidaka Y, Abe H, Tsuzuki T, Ito K, Kojima T, Kato M, Hatakeyama S, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Kamiyama M, Morita S, Habuchi T, Ogawa O, Nishiyama H, Kitamura H, Kobayashi T. Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis. BJU Int 2021; 130:226-234. [PMID: 34110696 DOI: 10.1111/bju.15510] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2021] [Revised: 05/04/2021] [Accepted: 06/03/2021] [Indexed: 11/24/2022]
Abstract
OBJECTIVES To assess the impact of histological variants on survival and response to treatment with pembrolizumab in patients with chemo-resistant urothelial carcinoma (UC). PATIENTS AND METHODS The medical records of 755 patients with advanced UC who received pembrolizumab were reviewed retrospectively. Patients were classified into pure UC (PUC) and each variant. Best overall response (BOR) and overall survival (OS) were compared between the groups using a propensity score matching (PSM). RESULTS Overall, 147 (19.5%) patients harboured any histological variant UC (VUC). After PSM, there were no significant differences in the objective response rate (ORR, 24.5% vs 17.3%, P = 0.098) or disease control rate (DCR, 36.7% vs 30.2%, P = 0.195) when comparing patients with any VUC and PUC. Furthermore, any VUC, as compared with PUC, was associated with a similar risk of death (hazard ratio [HR] 0.90, 95% confidence interval [CI] 0.68-1.20; P = 0.482). Squamous VUC, which was the most frequent variant in the cohort, had a comparable ORR, DCR and OS as compared with PUC or non-squamous VUC. The patients with sarcomatoid VUC (n = 19) had significantly better ORR (36.8%, P = 0.031), DCR (52.6%, P = 0.032), and OS (HR 0.37, 95% CI 0.15-0.90; P = 0.023) compared to patients with PUC. CONCLUSIONS The presence of variant histology did not seem to affect BOR or OS after pembrolizumab administration in patients with chemo-resistant UC. The patients with sarcomatoid VUC achieved favourable responses and survival rates compared to PUC.
Collapse
Affiliation(s)
- Mizuki Kobayashi
- Department of Urology, Akita University Graduate School of Medicine, Akita, Japan
| | - Shintaro Narita
- Department of Urology, Akita University Graduate School of Medicine, Akita, Japan
| | - Yoshiyuki Matsui
- Department of Urology, National Cancer Center Hospital, Tokyo, Japan
| | - Souhei Kanda
- Department of Urology, Akita University Graduate School of Medicine, Akita, Japan
| | - Yu Hidaka
- Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Hiroyasu Abe
- Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Toyonori Tsuzuki
- Department of Surgical Pathology, Aichi Medical University, Nagoya, Japan
| | - Katsuhiro Ito
- Department of Urology, Ijinkai Takeda General Hospital, Kyoto, Japan
| | | | - Minoru Kato
- Department of Urology, Osaka City University, Osaka, Japan
| | | | - Yuto Matsushita
- Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Sei Naito
- Department of Urology, Faculty of Medicine, Yamagata University, Yamagata, Japan
| | | | - Makito Miyake
- Department of Urology, Nara Medical University, Kashihara, Japan
| | - Yusuke Muro
- Department of Urology, Shizuoka General Hospital, Shizuoka, Japan
| | | | - Yoichiro Kato
- Department of Urology, Iwate Medical University, Morioka, Japan
| | | | | | | | - Takashi Yoshida
- Department of Urology, Kansai Medical University, Hirakata, Japan
| | | | - Rikiya Taoka
- Department of Urology, Kagawa University, Kita, Japan
| | | | - Satoshi Morita
- Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Tomonori Habuchi
- Department of Urology, Akita University Graduate School of Medicine, Akita, Japan
| | - Osamu Ogawa
- Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | | | | | - Takashi Kobayashi
- Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | | |
Collapse
|
13
|
Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata K, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Inoue T, Mizowaki T, Kamoto T, Kojima T, Kitamura H, Sugimoto M, Nishiyama H, Eto M. Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients. Cancer Sci 2021; 112:1524-1533. [PMID: 33159829 PMCID: PMC8019198 DOI: 10.1111/cas.14722] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2020] [Revised: 11/01/2020] [Accepted: 11/03/2020] [Indexed: 01/08/2023] Open
Abstract
Metastatic burden is a critical factor for therapy decision-making in metastatic hormone-sensitive prostate cancer. The present study aimed to identify prognostic factors in men with high- or low-metastatic burden treated with primary androgen-deprivation therapy. The study included 2450 men with de novo metastatic prostate cancer who were treated with primary androgen-deprivation therapy at 30 institutions across Japan between 2008 and 2017. We investigated the prognostic value of various clinicopathological parameters for progression-free survival (PFS) and overall survival (OS) in patients stratified by low- or high-metastatic burden. Among the 2450 men, 841 (34.3%) and 1609 (65.7%) were classified as having low- and high-metastatic burden, respectively. Median PFS of the low- and high-burden groups were 44.5 and 16.1 months, respectively, and the median OS was 103.2 and 62.7 months, respectively. Percentage of biopsy-positive core, biopsy Gleason grade group, T-stage, and N-stage were identified to be differentially prognostic. M1a was associated with worse PFS than was M1b in the low-burden group, whereas lung metastasis was associated with better PFS and OS than was M1b in the high-burden group. Differential prognostic factors were identified for patients with low- and high-burden metastatic prostate cancer. These results may assist in decision-making to select the optimal therapeutic strategies for patients with different metastatic burdens.
Collapse
Affiliation(s)
| | - Naoki Terada
- Department of UrologyMiyazaki UniversityMiyazakiJapan
| | - Toshihiro Saito
- Department of UrologyNiigata Cancer Center HospitalNiigataJapan
| | | | - Naoki Kohei
- Department of UrologyShizuoka General HospitalShizuokaJapan
| | | | | | | | | | | | | | - Ryotaro Tomida
- Department of UrologyShikoku Cancer CenterMatsuyamaJapan
| | | | | | - Toru Shimazui
- Department of UrologyIbaraki Prefectural Central HospitalIbaraki Cancer CenterKasamaJapan
| | | | - Manabu Kamiyama
- Department of UrologyUniversity of Yamanashi HospitalChuoJapan
| | | | | | - Takuma Kato
- Department of UrologyKagawa UniversityKagawaJapan
| | | | | | | | - Masashi Kato
- Department of UrologyNagoya UniversityNagoyaJapan
| | - Takahiro Osawa
- Department of Renal and Genitourinary SurgeryHokkaido UniversitySapporoJapan
| | | | | | | | - Takayuki Sugiyama
- Department of UrologyHamamatsu University School of MedicineHamamatsuJapan
| | - Kentaro Kuroiwa
- Department of UrologyMiyazaki Prefectural Miyazaki HospitalMiyazakiJapan
| | | | - Takashi Mizowaki
- Department of Radiation Oncology & Image‐Applied TherapyKyoto UniversityKyotoJapan
| | | | - Takahiro Kojima
- Department of UrologyUniversity of Tsukuba HospitalTsukubaJapan
| | - Hiroshi Kitamura
- Department of UrologyGraduate School of Medicine and Pharmaceutical Sciences for ResearchUniversity of ToyamaToyamaJapan
| | | | | | | | | |
Collapse
|
14
|
Kobayashi T, Ito K, Kojima T, Kato M, Kanda S, Hatakeyama S, Matsui Y, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Kamiyama M, Ogawa O, Kitamura H, Nishiyama H. Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab. Cancer Sci 2020; 112:760-773. [PMID: 33283385 PMCID: PMC7893997 DOI: 10.1111/cas.14762] [Citation(s) in RCA: 44] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2020] [Revised: 11/28/2020] [Accepted: 12/01/2020] [Indexed: 12/14/2022] Open
Abstract
The use of immune checkpoint inhibitors to treat urothelial carcinoma (UC) is increasing rapidly without clear guidance for validated risk stratification. This multicenter retrospective study collected clinicopathological information on 463 patients, and 11 predefined variables were analyzed to develop a multivariate model predicting overall survival (OS). The model was validated using an independent dataset of 292 patients. Patient characteristics and outcomes were well balanced between the discovery and validation cohorts, which had median OS times of 10.2 and 12.5 mo, respectively. The final validated multivariate model was defined by risk scores based on the hazard ratios (HRs) of independent prognostic factors including performance status, site of metastasis, hemoglobin levels, and the neutrophil‐to‐lymphocyte ratio. The median OS times (95% confidence intervals [CIs]) for the low‐, intermediate‐, and high‐risk groups (discovery cohort) were not yet reached (NYR) (NYR–19.1), 6.8 mo (5.8‐8.9), and 2.3 mo (1.2‐2.6), respectively. The HRs (95% CI) for OS in the low‐ and intermediate‐risk groups vs the high‐risk group were 0.07 (0.04‐0.11) and 0.23 (0.15‐0.37), respectively. The objective response rates for in the low‐, intermediate‐, and high‐risk groups were 48.3%, 28.8%, and 10.5%, respectively. These differential outcomes were well reproduced in the validation cohort and in patients who received pembrolizumab after perioperative or first‐line chemotherapy (N = 584). In conclusion, the present study developed and validated a simple prognostic model predicting the oncological outcomes of pembrolizumab‐treated patients with chemoresistant UC. The model provides useful information for external validation, patient counseling, and clinical trial design.
Collapse
Affiliation(s)
- Takashi Kobayashi
- Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Katsuhiro Ito
- Department of Urology, Ijinkai Takeda General Hospital, Kyoto, Japan
| | - Takahiro Kojima
- Department of Urology, University of Tsukuba, Tsukuba, Japan
| | - Minoru Kato
- Department of Urology, Osaka City University, Osaka, Japan
| | - Souhei Kanda
- Department of Urology, Akita University, Akita, Japan
| | | | - Yoshiyuki Matsui
- Department of Urology, National Cancer Center Hospital, Tokyo, Japan
| | - Yuto Matsushita
- Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Sei Naito
- Department of Urology, Faculty of Medicine, Yamagata University, Yamagata, Japan
| | - Masanobu Shiga
- Department of Urology, University of Tsukuba, Tsukuba, Japan
| | - Makito Miyake
- Department of Urology, Nara Medical University, Kashihara, Japan
| | - Yusuke Muro
- Department of Urology, Shizuoka General Hospital, Shizuoka, Japan
| | | | - Yoichiro Kato
- Department of Urology, Iwate Medical University, Morioka, Japan
| | | | | | | | - Takashi Yoshida
- Department of Urology, Kansai Medical University, Hirakata, Japan
| | | | - Rikiya Taoka
- Department of Urology, Kagawa University, Kita, Japan
| | | | - Osamu Ogawa
- Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | | | | | | |
Collapse
|
15
|
Terada N, Mizowaki T, Saito T, Yokomizo A, Kohei N, Tabata K, Shiota M, Takahashi A, Shimazui T, Goto T, Hashimoto Y, Fujii M, Tomida R, Sakurai T, Hashimoto K, Kawamura S, Teraoka S, Sakamoto S, Kimura T, Kamiyama M, Narita S, Tanaka N, Kato T, Kato M, Osawa T, Kojima T, Inoue T, Sugimoto M, Nishiyama H, Kamoto T. Potential effectiveness of local radiotherapy for extending survival and reducing symptomatic local events in patients with de novo metastatic prostate cancer. BJUI Compass 2020; 1:165-173. [PMID: 35475210 PMCID: PMC8988774 DOI: 10.1002/bco2.35] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2020] [Revised: 06/16/2020] [Accepted: 07/12/2020] [Indexed: 01/06/2023] Open
Abstract
Objectives To evaluate the association between the use of local radiotherapy (RT) with the survival of patients with de novo metastatic prostate cancer and symptomatic local events (SLEs). Patients and methods Patients were initially diagnosed with metastatic prostate cancer between 2008 and 2017 at 30 institutes in Japan. Prostate‐specific antigen (PSA) progression‐free survival (PSA‐PFS) under initial androgen deprivation therapy and overall survival (OS) was compared between patients receiving local RT (RT group) and no RT (no‐RT group) by multivariate Cox proportional hazard analyses. The occurrence rate of grade ≥2 SLEs was compared by multivariate logistic regression analyses. Propensity score matching (PSM) analyses were performed to compare PSA‐PFS and OS of the groups in the high and low metastatic burden cohort. Results Two hundred and five (7%) of 2829 patients received RT before PSA progression. Median PSA‐PFS and OS were significantly longer in the RT group than in the no‐RT group and the difference was significant in multivariate analyses (HR = 0.44, 95% CI = 0.33‐0.57 and HR = 0.40, 95% CI = 0.27‐0.60, respectively). The occurrence rate of grade ≥2 SLEs was significantly lower in the RT group (2%) than the no‐RT group (9%) and the difference was significant in multivariate analyses (HR = 0.28, 95% CI = 0.10‐0.76). Using PSM analyses, PSA‐PFS and OS remained significantly different (HR = 0.64, 95% CI = 0.46‐0.89 and HR = 0.47, 95% CI = 0.30‐0.72, respectively), between the RT (n = 182) and the no‐RT (n = 182) groups. The difference in OS was significant in the high metastatic burden cohort (HR = 0.55, 95% CI = 0.37‐0.81). Conclusions Addition of local RT to standard treatment for de novo metastatic prostate cancer patients tends to have the potential to extend survival, even in patients with high metastatic burden, and to reduce SLEs.
Collapse
Affiliation(s)
- Naoki Terada
- Department of Urology Miyazaki University Miyazaki Japan
| | - Takashi Mizowaki
- Department of Radiation Oncology & Image‐applied Therapy Kyoto University Kyoto Japan
| | - Toshihiro Saito
- Department of Urology Niigata Cancer Center Hospital Niigata Japan
| | - Akira Yokomizo
- Department of Urology Harasanshin Hospital Fukuoka Japan
| | - Naoki Kohei
- Department of Urology Shizuoka General Hospital Shizuoka Japan
| | | | - Masaki Shiota
- Department of Urology Kyushu University Fukuoka Japan
| | | | - Toru Shimazui
- Department of Urology Ibaraki Prefectural Central HospitalIbaraki Cancer Center Kasama Japan
| | | | | | - Masato Fujii
- Department of Urology Miyazaki University Miyazaki Japan
| | - Ryotaro Tomida
- Department of Urology Shikoku Cancer Center Matsuyama Japan
| | | | - Kohei Hashimoto
- Department of Urology Sapporo Medical University Sapporo Japan
| | | | - Shogo Teraoka
- Department of Urology Tottori University Yonago Japan
| | | | | | - Manabu Kamiyama
- Department of Urology University of Yamanashi Hospital Chuo Japan
| | | | | | - Takuma Kato
- Department of Urology Kagawa University Kagawa Japan
| | - Masashi Kato
- Department of Urology Nagoya University Nagoya Japan
| | - Takahiro Osawa
- Department of Renal and Genitourinary surgery Hokkaido University Sapporo Japan
| | - Takahiro Kojima
- Department of Urology University of Tsukuba Hospital Tsukuba Japan
| | | | | | | | | | | |
Collapse
|
16
|
Mizokami A, Takahashi S, Matsuyama H, Kaneko G, Shiina H, Ichikawa T, Horikoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A, Nakajima K. Evaluation of bone metastasis and prognosis of prostate cancer with bone metastasis during standard hormonal therapy and chemotherapy: A report of PROSTAT-BSI multicenter registry in Japan. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.6_suppl.215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
215 Background: Quantitative evaluation of the change of bone metastasis (bMet) has not been clearly defined during treatments in prostate cancer (PCa). As therapeutic effects of bMet have become quantified with scintigraphic bone scan index (BSI), we performed a nation-wide observational prospective study in patients who were treated by hormonal therapy (HTx) or chemotherapy (CTx). Methods: A total of 237 patients were recruited at 30 hospitals in Japan, and this report summarized baseline demographics and prognosis of 203 patients. All had bMet and underwent either standard HTx (group H) or docetaxel CTx (group C). Bone scans were performed with 99mTc-MDP. Patients were followed up for 3 years, and changes in biochemical and tumor markers during HTx and CTx were recorded in addition to skeletal-related events, recurrence, and death. Results: The basic characteristics of the patients (n=203) at the time of registration during December 2016 were as follows: mean age 71 ± 8 years; median BSI calculated on-site 3.0 ± 3.2% and median PSA was 265 ng/mL (22-2923 ng/mL) and 33 (3-537 ng/mL), for Group H and C (p=0.0014), respectively. BSI was comparable (H: 3.0 ± 3.4 vs C: 3.0 ± 2.8%, p=n.s.) between the two groups. A total of 54 patients (24%) died from PCa. BSI flare defined as increase at 3 months and decrease at 6 months was 13% and 31% (p<0.0069) for Groups H and C, respectively. When patients were classified into three groups with BSI <0.9 (low), 0.9-3.3 (intermediate), and >3.3% (high). Kaplan-Meier Survival analysis showed that mortality at 1100 days was 8%, 16%, and 35% for Group H (p=0.0097), and 50%, 55%, and 65% for Group C (p=ns) for the low, intermediate and high BSI group, respectively. In addition, patients who showed BSI decline >20% until 6 months showed better prognosis than those who did not (p<0.0001 and p= 0.038 and for Group H and C, respectively). Conclusions: The data of PROSTAT-BSI showed that BSI could be a good biomarker for prognosis in both Groups H and C, in particular for prognostic stratification of patients indicated for HTx. Six-month response of BSI by >20% indicated better prognosis in both groups. Clinical trial information: UMIN000007858.
Collapse
Affiliation(s)
- Atsushi Mizokami
- Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
| | - Satoru Takahashi
- Department of Experimental Pathology and Tumor Biology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
| | | | - Gou Kaneko
- Department of Urology, Keio University School of Medicine, Tokyo, Japan
| | - Hiroaki Shiina
- Department of Urology, Shimane University Faculty of Medicine, Matsue, Japan
| | - Tomohiko Ichikawa
- Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Hiroyuki Horikoshi
- Department of Diagnostic Radiology, Gunma Prefectural Cancer Center, Ota, Japan
| | | | - Yutaka Sugiyama
- Department of Urology, Kumamoto University Faculty of Life Sciences, Kumamoto, Japan
| | | | - Manabu Kamiyama
- Department of Urology, Yamanashi University School of Medicine, Yamanashi, Japan
| | - Kenichi Harada
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Akito Ito
- Department of Urology, Iwate Medical University, Morioka, Morioka, Japan
| | - Kenichi Nakajima
- Department of Nuclear Medicine, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
| | | |
Collapse
|
17
|
Ihara T, Nakamura Y, Mitsui T, Tsuchiya S, Kanda M, Kira S, Nakagomi H, Sawada N, Kamiyama M, Shigetomi E, Shinozaki Y, Yoshiyama M, Nakao A, Koizumi S, Takeda M. Author Correction: Intermittent restraint stress induces circadian misalignment in the mouse bladder, leading to nocturia. Sci Rep 2019; 9:16731. [PMID: 31700120 PMCID: PMC6838461 DOI: 10.1038/s41598-019-53132-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Affiliation(s)
- Tatsuya Ihara
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Yuki Nakamura
- Department of Immunology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Takahiko Mitsui
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
| | - Sachiko Tsuchiya
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Mie Kanda
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Satoru Kira
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Hiroshi Nakagomi
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Norifumi Sawada
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Manabu Kamiyama
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Eiji Shigetomi
- Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Youichi Shinozaki
- Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Mitsuharu Yoshiyama
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Atsuhito Nakao
- Department of Immunology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Schuichi Koizumi
- Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Masayuki Takeda
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
| |
Collapse
|
18
|
Funayama S, Onishi H, Kuriyama K, Komiyama T, Marino K, Araya M, Saito R, Aoki S, Maehata Y, Nonaka H, Tominaga L, Muramatsu J, Nakagomi H, Kamiyama M, Takeda M. Renal Cancer is Not Radioresistant: Slowly but Continuing Shrinkage of the Tumor After Stereotactic Body Radiation Therapy. Technol Cancer Res Treat 2019; 18:1533033818822329. [PMID: 30803362 PMCID: PMC6373992 DOI: 10.1177/1533033818822329] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Purpose: To evaluate the safety and efficacy of stereotactic body radiation therapy for primary lesion of renal cell carcinoma with long-term and regular follow-up of tumor size and renal function. Methods: This prospective study included 13 patients treated with stereotactic body radiation therapy for primary lesion of stage I renal cell carcinoma between August 2007 and June 2016 in our institution. Diagnosis of renal cell carcinoma was made by 2 radiologists using computed tomography or magnetic resonance imaging. A dosage of 60 Gy in 10 fractions or 70 Gy in 10 fractions was prescribed. The higher dose was selected if dose constraints were satisfied. Tumor response on imaging examination, local progression-free rate, overall survival, and toxicity were assessed. Results: The mean follow-up period was 48.3 months (range: 11-108 months). The tumors showed very slow but continuous response during long-term follow-up. Three cases (23.1%) showed transient progression during the short follow-up. The mean duration until the day on which partial response was confirmed among the partial or complete response cases was 22.6 months (95% confidence interval, 15.3-30.0 months). Local progression-free rate was 92.3% for 3 years and overall survival rate 91.7% for 2 years and 71.3% for 3 years. Twelve cases (92.3%) had impaired renal function at baseline. Renal function decreased slowly and mildly in most of the cases, but 2 cases of solitary kidney showed grade 4 or 5 renal dysfunction. Conclusion: All renal tumors decreased in size slowly but continuously for years after stereotactic body radiation therapy. Renal cancer can be treated radically with stereotactic body radiation therapy as a radiosensitive tumor, but careful attention should be given in cases with solitary kidney.
Collapse
Affiliation(s)
- Satoshi Funayama
- 1 Department of Radiology, School of Medicine, University of Yamanashi, Yamanashi, Japan
| | - Hiroshi Onishi
- 1 Department of Radiology, School of Medicine, University of Yamanashi, Yamanashi, Japan
| | - Kengo Kuriyama
- 2 Department of Radiology, Shizuoka General Hospital, Shizuoka, Japan
| | - Takafumi Komiyama
- 1 Department of Radiology, School of Medicine, University of Yamanashi, Yamanashi, Japan
| | - Kan Marino
- 1 Department of Radiology, School of Medicine, University of Yamanashi, Yamanashi, Japan
| | - Masayuki Araya
- 3 Department of Radiology, Center of Proton Therapy, Aizawa Hospital, Nagano, Japan
| | - Ryo Saito
- 1 Department of Radiology, School of Medicine, University of Yamanashi, Yamanashi, Japan
| | - Shinichi Aoki
- 1 Department of Radiology, School of Medicine, University of Yamanashi, Yamanashi, Japan
| | - Yoshiyasu Maehata
- 1 Department of Radiology, School of Medicine, University of Yamanashi, Yamanashi, Japan
| | - Hotaka Nonaka
- 4 Department of Radiology, Fujiyoshida Municipal Medical Center, Yamanashi, Japan
| | - Licht Tominaga
- 5 Department of Radiology, Toranomon Hospital, Tokyo, Japan
| | - Juria Muramatsu
- 1 Department of Radiology, School of Medicine, University of Yamanashi, Yamanashi, Japan
| | - Hiroshi Nakagomi
- 6 Department of Urology, School of Medicine, University of Yamanashi, Yamanashi, Japan
| | - Manabu Kamiyama
- 6 Department of Urology, School of Medicine, University of Yamanashi, Yamanashi, Japan
| | - Masayuki Takeda
- 6 Department of Urology, School of Medicine, University of Yamanashi, Yamanashi, Japan
| |
Collapse
|
19
|
Shitara H, Ichinose T, Hamano N, Sasaki T, Shimoyama D, Kamiyama M, Miyamoto R, Chikuda H. Transcranial Direct Current Stimulation (tDCS) for Postoperative pain relief in Arthroscopic Rotator Cuff Repair. Brain Stimul 2019. [DOI: 10.1016/j.brs.2018.12.858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
20
|
Ihara T, Mitsui T, Nakamura Y, Kanda M, Tsuchiya S, Kira S, Nakagomi H, Sawada N, Kamiyama M, Shigetomi E, Shinozaki Y, Yoshiyama M, Nakao A, Takeda M, Koizumi S. The time-dependent variation of ATP release in mouse primary-cultured urothelial cells is regulated by the clock gene. Neurourol Urodyn 2018; 37:2535-2543. [PMID: 30106187 DOI: 10.1002/nau.23793] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2018] [Accepted: 06/15/2018] [Indexed: 11/10/2022]
Abstract
AIMS The sensation of bladder fullness (SBF) is triggered by the release of ATP. Therefore, the aim of this study was to investigate whether time-dependent changes in the levels of stretch-released ATP in mouse primary-cultured urothelial cells (MPCUCs) is regulated by circadian rhythm via clock genes. METHODS MPCUCs were derived from wild-type and Clock mutant mice (ClockΔ19/Δ19 ), presenting a nocturia phenotype. They were cultured in elastic silicone chambers. Stretch-released ATP was quantified every 4 h by ATP photon count. An experiment was also performed to determine whether ATP release correlated with the rhythm of the expression of Piezo1, TRPV4, VNUT, and Connexin26 (Cx26) in MPCUCs regulated by clock genes with circadian rhythms. MPCUCs were treated with carbenoxolone, an inhibitor of gap junction protein; were derived from VNUT-KO mice; or treated with Piezo1-siRNA, TRPV4-siRNA, and Cx26-siRNA. RESULTS Stretch-released ATP showed time-dependent changes in wild-type mice and correlated with the rhythm of the expression of Piezo1, TRPV4, VNUT, and Cx26. However, these rhythms were disrupted in ClockΔ19/Δ19 mice. Carbenoxolone eliminated the rhythmicity of ATP release in wild-type mice. However, time-dependent ATP release changes were maintained when a single gene was deficient such as VNUT-KO, Piezo1-, TRPV4-, and Cx26-siRNA. CONCLUSIONS ATP release in the bladder urothelium induces SBF and may have a circadian rhythm regulated by the clock genes. In the bladder urothelium, clock gene abnormalities may disrupt circadian ATP release by inducing Piezo1, TRPV4, VNUT, and Cx26. All these genes can trigger nocturia.
Collapse
Affiliation(s)
- Tatsuya Ihara
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Takahiko Mitsui
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Yuki Nakamura
- Department of Immunology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Mie Kanda
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Sachiko Tsuchiya
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Satoru Kira
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Hiroshi Nakagomi
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Norifumi Sawada
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Manabu Kamiyama
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Eiji Shigetomi
- Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Youichi Shinozaki
- Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Mitsuharu Yoshiyama
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Atsuhito Nakao
- Department of Immunology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Masayuki Takeda
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Schuichi Koizumi
- Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| |
Collapse
|
21
|
Ihara T, Mitsui T, Nakamura Y, Kanda M, Tsuchiya S, Kira S, Nakagomi H, Sawada N, Kamiyama M, Hirayama Y, Shigetomi E, Shinozaki Y, Yoshiyama M, Nakao A, Takeda M, Koizumi S. The oscillation of intracellular Ca 2+ influx associated with the circadian expression of Piezo1 and TRPV4 in the bladder urothelium. Sci Rep 2018; 8:5699. [PMID: 29632308 PMCID: PMC5890282 DOI: 10.1038/s41598-018-23115-w] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2017] [Accepted: 03/06/2018] [Indexed: 11/09/2022] Open
Abstract
We previously showed that bladder functions are controlled by clock genes with circadian rhythm. The sensation of bladder fullness (SBF) is sensed by mechano-sensor such as Piezo1 and TRPV4 in the mouse bladder urothelium. However, functional circadian rhythms of such mechano-sensors remain unknown. To investigate functional circadian changes of these mechano-sensors, we measured circadian changes in stretch-evoked intracellular Ca2+ influx ([Ca2+] i ) using mouse primary cultured urothelial cells (MPCUCs). Using Ca2+ imaging, stretch-evoked [Ca2+] i was quantified every 4 h in MPCUCs derived from wild-type (WT) and Clock Δ19/Δ19 mice, which showed a nocturia phenotype. Furthermore, a Piezo1 inhibitor GsMTx4 and a TRPV4 inhibitor Ruthenium Red were applied and stretch-evoked [Ca2+] i in MPCUCs was measured to investigate their contribution to SBF. Stretch-evoked [Ca2+] i showed a circadian rhythm in the WT mice. In contrast, Clock Δ19/Δ19 mice showed disrupted circadian rhythm. The administration of both GsMTx4 and Ruthenium Red eliminated the circadian rhythm of stretch-evoked [Ca2+] i in WT mice. We conclude that SBF may have a circadian rhythm, which is created by functional circadian changes of Piezo1 and TRPV4 being controlled by clock genes to be active during wakefulness and inactive during sleep. Abnormalities of clock genes disrupt SBF, and induce nocturia.
Collapse
Affiliation(s)
- Tatsuya Ihara
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Takahiko Mitsui
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Yuki Nakamura
- Department of Immunology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Mie Kanda
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Sachiko Tsuchiya
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Satoru Kira
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Hiroshi Nakagomi
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Norifumi Sawada
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Manabu Kamiyama
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Yuri Hirayama
- Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Eiji Shigetomi
- Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Youichi Shinozaki
- Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Mitsuharu Yoshiyama
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Atsuhito Nakao
- Department of Immunology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Masayuki Takeda
- Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
| | - Schuichi Koizumi
- Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
| |
Collapse
|
22
|
Nakajima K, Kaneko G, Takahashi S, Matsuyama H, Shiina H, Ichikawa T, Horikoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A, Mizokami A. Role of bone scan index in the prognosis and effects of therapy on prostate cancer with bone metastasis: Study design and rationale for the multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index (PROSTAT-BSI) stu. Int J Urol 2018; 25:492-499. [DOI: 10.1111/iju.13556] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2017] [Accepted: 02/09/2018] [Indexed: 02/06/2023]
Affiliation(s)
- Kenichi Nakajima
- Department of Nuclear Medicine; Kanazawa University Hospital; Kanazawa Japan
| | - Go Kaneko
- Department of Uro-Oncology; Saitama Medical University International Medical Center; Saitama Japan
| | - Satoru Takahashi
- Department of Urology; Nihon University School of Medicine; Tokyo Japan
| | - Hideyasu Matsuyama
- Department of Urology; Graduate School of Medicine; Yamaguchi University; Ube Japan
| | - Hiroaki Shiina
- Department of Urology; Shimane University; Faculty of Medicine; Shimane Japan
| | - Tomohiko Ichikawa
- Department of Urology; Graduate School of Medicine; Chiba University; Chiba Japan
| | - Hiroyuki Horikoshi
- Department of Diagnostic Radiology; Gunma Prefectural Cancer Center; Ota Japan
| | - Katsuyoshi Hashine
- Department of Urology; National Hospital Organization Shikoku Cancer Center; Matsuyama Japan
| | - Yutaka Sugiyama
- Department of Urology; Graduate School of Medical Sciences; Kumamoto University; Kumamoto , Japan
| | - Takeshi Miyao
- Department of Urology; Gunma University; Graduate School of Medicine; Maebashi Japan
| | - Manabu Kamiyama
- Department of Urology; Yamanashi University School of Medicine; Yamanashi Japan
| | - Kenichi Harada
- Division of Urology; Department of Surgery Related; Kobe University Graduate School of Medicine; Kobe , Japan
| | - Akito Ito
- Department of Urology; Iwate Medical University; Morioka Japan
| | - Atsushi Mizokami
- Department of Integrative Cancer Therapy and Urology; Kanazawa University Graduate School of Medical Science; Kanazawa Japan
| | | |
Collapse
|
23
|
Shamsuzzaman M, Horie T, Fuke F, Kamiyama M, Morioka T, Matsumoto T, Morita K, Tagami H, Suzuki T, Tobita Y. Experimental study on debris bed characteristics for the sedimentation behavior of solid particles used as simulant debris. ANN NUCL ENERGY 2018. [DOI: 10.1016/j.anucene.2017.09.011] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
24
|
Izumi K, Mizokami A, Namiki M, Inoue S, Tanaka N, Yoshio Y, Ishibashi K, Kamiyama M, Kawai N, Enokida H, Shima T, Takahara S. Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial. BMC Cancer 2017; 17:677. [PMID: 29017493 PMCID: PMC5635584 DOI: 10.1186/s12885-017-3661-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2016] [Accepted: 09/28/2017] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Both enzalutamide and abiraterone have demonstrated improved radiographic progression-free and overall survival for castration-resistant prostate cancer (CRPC) compared with placebo controls before docetaxel treatment in phase III studies. These oral agents target androgen and androgen receptor signaling and are thought to be less toxic than chemotherapy. Cross-resistance to these agents was recently reported because of their similar mechanism of action, and it is important to assess which agent is more effective to use initially for CRPC. METHODS/DESIGN The present study is a phase III, investigator-initiated, multicenter, head-to-head, randomized controlled trial investigating enzalutamide vs. abiraterone as a first-line treatment for CRPC patients. Patients will be randomly assigned to an enzalutamide or an abiraterone treatment group. The primary endpoint is the time to prostate-specific antigen progression. The target sample size is set at 100 patients per group (total, 200 patients). The study duration is 5 years, and the duration for recruitment is 2 years and 6 months. DISCUSSION Thus far, there have been no prospective head-to-head studies comparing enzalutamide and abiraterone. This ENABLE study will clarify which agent should be prioritized for CRPC patients and enable clinicians to decide the appropriate treatment before chemotherapy. TRIAL REGISTRATION University hospital Medical Information Network (UMIN) Center identifier UMIN000015529 . Registrated 11/1/2014.
Collapse
Affiliation(s)
- Kouji Izumi
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.
| | - Atsushi Mizokami
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Mikio Namiki
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Shogo Inoue
- Department of Urology, Institute of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan
| | | | - Yuko Yoshio
- Nephro-Urologic Surgery and Andrology, Division of Reparative and Regenerative Medicine, Institute of Medical Life Science, Mie University Graduate School of Medicine, Tsu, Japan
| | - Kei Ishibashi
- Department of Urology, Fukushima Medical University, Fukushima, Japan
| | | | - Noriyasu Kawai
- Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
| | - Hideki Enokida
- Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
| | - Takashi Shima
- Department of Urology, Toyama Prefectural Central Hospital, Toyama, Japan
| | - Shizuko Takahara
- Innovative Clinical Research Center, Kanazawa University, Kanazawa, Japan
| |
Collapse
|
25
|
Zhang X, Gao S, Tanaka M, Zhang Z, Huang Y, Mitsui T, Kamiyama M, Koizumi S, Fan J, Takeda M, Yao J. Carbenoxolone inhibits TRPV4 channel-initiated oxidative urothelial injury and ameliorates cyclophosphamide-induced bladder dysfunction. J Cell Mol Med 2017; 21:1791-1802. [PMID: 28244642 PMCID: PMC5571544 DOI: 10.1111/jcmm.13100] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2016] [Accepted: 12/25/2016] [Indexed: 01/23/2023] Open
Abstract
Carbenoxolone (CBX) is a clinically prescribed drug for the treatment of digestive ulcer and inflammation. It is also a widely used pharmacological inhibitor of several channels in basic research. Given that the overactivity of several channels, including those inhibitable by CBX, underlies bladder dysfunction, we tested the potential therapeutic application and mechanism of CBX in the treatment of voiding dysfunction. In a mouse model of cystitis induced by cyclophosphamide (CYP), CBX administration prevented the CYP‐elicited increase in bladder weight, oedema, haemorrhage, and urothelial injury. CBX also greatly improved micturition pattern, as manifested by the apparently decreased micturition frequency and increased micturition volume. Western blot results showed that CBX suppressed CYP‐induced increase in protein carbonyls, COX‐2, and iNOS. Further analysis using cultured urothelial cells revealed that acrolein, the major metabolite of CYP, caused protein oxidation, p38 activation, and urothelial injury. These effects of acrolein were reproduced by TRPV4 agonists and significantly prevented by antioxidant NAC, p38 inhibitor SB203580, TRPV4 antagonist RN‐1734, and CBX. Further studies showed that CBX potently suppressed TRPV4 agonist‐initiated calcium influx and subsequent cell injury. CBX attenuated CYP‐induced cystitis in vivo and reduced acrolein‐induced cell injury in vitro, through mechanisms involving inhibition of TRPV4 channels and attenuation of the channel‐mediated oxidative stress. CBX might be a promising agent for the treatment of bladder dysfunction.
Collapse
Affiliation(s)
- Xiling Zhang
- Division of Molecular Signaling, Department of Advanced Biomedical Research, University of Yamanashi, Yamanashi, Japan.,China Medical University, Shenyang, China
| | - Shan Gao
- Division of Molecular Signaling, Department of Advanced Biomedical Research, University of Yamanashi, Yamanashi, Japan.,China Medical University, Shenyang, China
| | - Masayoshi Tanaka
- Department of Neuropharmacology, University of Yamanashi, Yamanashi, Japan
| | - Zhen Zhang
- Division of Molecular Signaling, Department of Advanced Biomedical Research, University of Yamanashi, Yamanashi, Japan
| | - Yanru Huang
- Division of Molecular Signaling, Department of Advanced Biomedical Research, University of Yamanashi, Yamanashi, Japan
| | - Takahiko Mitsui
- Department of Urology, University of Yamanashi, Yamanashi, Japan
| | - Manabu Kamiyama
- Department of Urology, University of Yamanashi, Yamanashi, Japan
| | - Schuichi Koizumi
- Department of Neuropharmacology, University of Yamanashi, Yamanashi, Japan
| | - Jianglin Fan
- Department of Molecular Pathology, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Yamanashi, Japan
| | - Masayuki Takeda
- Department of Urology, University of Yamanashi, Yamanashi, Japan
| | - Jian Yao
- Division of Molecular Signaling, Department of Advanced Biomedical Research, University of Yamanashi, Yamanashi, Japan
| |
Collapse
|
26
|
Shimura H, Mitsui T, Aoki T, Kamiyama M, Yamagishi T, Takeda M. Persistent Urinary Incontinence After Nephrectomy: A Case of Inverted-Y Ureteral Duplication with Ectopic Ureteral Insertion into the Vagina. Urol Case Rep 2016; 9:58-61. [PMID: 27747162 PMCID: PMC5061114 DOI: 10.1016/j.eucr.2016.09.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2016] [Revised: 08/30/2016] [Accepted: 09/07/2016] [Indexed: 12/16/2022] Open
Abstract
Inverted-Y ureteral duplication is one of the rarest anomalies of ureteral branching. We encountered a 20-year-old female patient with persistent incontinence even after nephrectomy for ectopic ureteral insertion into the vagina. She had inverted-Y ureteral duplication between the bladder and vagina, and urine was being transported from the bladder to the vagina. To the best of our knowledge, this is a rare case of inverted-Y ureteral duplication with ectopic ureteral insertion into the vagina as well as the ureter into the bladder, which became apparent due to persistent urinary incontinence even after nephrectomy.
Collapse
Affiliation(s)
- Hiroshi Shimura
- Department of Urology, University of Yamanashi Graduate School of Medical Science, Chuo, Yamanashi, Japan
| | - Takahiko Mitsui
- Department of Urology, University of Yamanashi Graduate School of Medical Science, Chuo, Yamanashi, Japan
| | - Tadashi Aoki
- Department of Urology, University of Yamanashi Graduate School of Medical Science, Chuo, Yamanashi, Japan
| | - Manabu Kamiyama
- Department of Urology, University of Yamanashi Graduate School of Medical Science, Chuo, Yamanashi, Japan
| | - Takashi Yamagishi
- Department of Urology, University of Yamanashi Graduate School of Medical Science, Chuo, Yamanashi, Japan
| | - Masayuki Takeda
- Department of Urology, University of Yamanashi Graduate School of Medical Science, Chuo, Yamanashi, Japan
| |
Collapse
|
27
|
Aoki M, Kamiyama M, Nagata T, Sakaguchi H, Ichii R. One Component Polyurethane Elastomers Based on Novel Polyaldimine. J CELL PLAST 2016. [DOI: 10.1177/0021955x9302900551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- M. Aoki
- Mitsui Toatsu Chemicals, Inc
| | | | | | | | | |
Collapse
|
28
|
Abstract
INTRODUCTION Apoptosis signal-regulating kinase 1 (ASK1) is a MAP3K in the JNK and p38 MAPK pathways and responds to various stresses. Accumulating evidence indicates that ASK1 plays important roles in tumorigenesis by regulating apoptosis and inflammation. However, little is known about ASK1's roles in tumor metastasis. AIM To investigate ASK1's roles in tumor metastasis. MATERIALS AND METHODS We performed experimental lung metastasis model by intravenous injection of Lewis lung carcinoma cells constitutively expressing luciferase (3LL-Luc2 cells). As for the analysis of platelet functions, tail bleeding assay and ferric chloride-induced thrombosis model were utilized. RESULTS We measured the transition of luciferase activity of the lung lysates up to 7 days as an indicator of lung metastasis. ASK1-/- mice showed markedly lower luciferase activity as early as 3 hours after injection compared to WT mice; hence ASK1 appears to be involved in the early stage of tumor lung metastasis, which is prior to the extravasation of tumor cells. Platelets aggregate and adhere to tumor cells in the early stage and are known to support hematogenous metastasis. ASK1-/- mice were normal in hematological parameters including platelet number, while analysis by western blot revealed that platelets of ASK1-/- mice exhibited markedly reduced phosphorylation of JNK and p38, both of which have been reported to regulate platelet functions such as platelet aggregation. We found that platelets of ASK1-/- mice were less responsive to specific aggregation agonists and that ASK1-/- mice showed bleeding tendency and defect in thrombosis. These phenotypes were also observed in megakaryocyte and platelet-specific ASK1 deficient mice. CONCLUSIONS It is suggested that impaired platelet functions caused by ASK1 deficiency in platelets may attenuate tumor lung metastasis.
Collapse
Affiliation(s)
- M Kamiyama
- Cell Signaling, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan
| | - I Naguro
- Cell Signaling, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan
| | - H Ichijo
- Cell Signaling, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan
| |
Collapse
|
29
|
Piao H, Chi Y, Zhang X, Zhang Z, Gao K, Niimi M, Kamiyama M, Zhang J, Takeda M, Yao J. Suramin inhibits antibody binding to cell surface antigens and disrupts complement-mediated mesangial cell lysis. J Pharmacol Sci 2016; 132:224-234. [PMID: 27103329 DOI: 10.1016/j.jphs.2016.03.011] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2015] [Revised: 02/27/2016] [Accepted: 03/22/2016] [Indexed: 11/29/2022] Open
Abstract
Suramin inhibits immune responses and protects cells against inflammatory cell injury. However, little is known about its mechanisms. Using an in vitro model of glomerular mesangial cell (MC) lysis induced by antibodies plus complement, we investigated the potential protective effects and mechanisms of suramin on immunologic cell injury. Exposure of rat MCs to anti-Thy-1 antibody plus complement or anti-MC rabbit serum caused complement-dependent cell lysis, which was blocked by suramin and its structural analogue NF023 and NF049, but not by PPADS, an antagonist of purinergic receptors. Addition of exogenous ATP also failed to affect MC lysis. Further analysis revealed that suramin interfered with antibody binding to cell membrane antigens and suppressed antibody-induced phosphorylation of several proteins, including p38. Inhibition of p38 with chemical inhibitor significantly attenuated cell injury. Collectively, our results indicate that suramin protects cells against antibody-initiated and complement-dependent cell injury through inhibition of antibody binding to cell surface antigens and suppression of p38 activation. Our study thus provides novel mechanistic insights into the actions of suramin and suggests that suramin might be used to treat certain immune diseases.
Collapse
Affiliation(s)
- Honglan Piao
- Department of Molecular Signaling, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Chuo, Yamanashi, Japan; Department of Rehabilitation, The First Affiliated Hospital, Harbin Medical University, Harbin, China
| | - Yuan Chi
- Department of Molecular Signaling, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Xiling Zhang
- Department of Molecular Signaling, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Zhen Zhang
- Department of Molecular Signaling, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Kun Gao
- Department of Molecular Signaling, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Manabu Niimi
- Department of Molecular Pathology, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Manabu Kamiyama
- Department of Urology, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Jinming Zhang
- Department of Rehabilitation, The First Affiliated Hospital, Harbin Medical University, Harbin, China
| | - Masayuki Takeda
- Department of Urology, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Jian Yao
- Department of Molecular Signaling, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Chuo, Yamanashi, Japan.
| |
Collapse
|
30
|
Zhang X, Yao J, Gao K, Chi Y, Mitsui T, Ihara T, Sawada N, Kamiyama M, Fan J, Takeda M. AMPK Suppresses Connexin43 Expression in the Bladder and Ameliorates Voiding Dysfunction in Cyclophosphamide-induced Mouse Cystitis. Sci Rep 2016; 6:19708. [PMID: 26806558 PMCID: PMC4726257 DOI: 10.1038/srep19708] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2015] [Accepted: 12/17/2015] [Indexed: 12/20/2022] Open
Abstract
Bladder voiding dysfunction is closely related to local oxidation, inflammation, and enhanced channel activities. Given that the AMP-activated protein kinase (AMPK) has anti-oxidative, anti-inflammatory and channel-inhibiting properties, we examined whether and how AMPK affected bladder activity. AMPK activation in rat bladder smooth muscle cells (BSMCs) using three different AMPK agonists resulted in a decrease in connexin43 (Cx43) expression and function, which was associated with reduced CREB phosphorylation, Cx43 promoter activity and mRNA expression, but not Cx43 degradation. Downregulation of CREB with siRNA increased Cx43 expression. A functional analysis revealed that AMPK weakened BSMC contraction and bladder capacity. AMPK also counteracted the IL-1β- and TNFα-induced increase in Cx43 in BSMCs. In vivo administration of the AMPK agonist AICAR attenuated cyclophosphamide-initiated bladder oxidation, inflammation, Cx43 expression and voiding dysfunction. Further analysis comparing the responses of the wild-type (Cx43(+/+)) and heterozygous (Cx43(+/-)) Cx43 mice to cyclophosphamide revealed that the Cx43(+/-) mice retained a relatively normal micturition pattern compared to the Cx43(+/+) mice. Taken together, our results indicate that AMPK inhibits Cx43 in BSMCs and improves bladder activity under pathological conditions. We propose that strategies that target AMPK can be developed as novel therapeutic approaches for treating bladder dysfunction.
Collapse
Affiliation(s)
- Xiling Zhang
- Department of Molecular Signaling, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Yamanashi, Japan
- Department of Urology, The 4th affiliated hospital of China Medical University, Shenyang, China
| | - Jian Yao
- Department of Molecular Signaling, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Yamanashi, Japan
| | - Kun Gao
- Department of Molecular Signaling, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Yamanashi, Japan
| | - Yuan Chi
- Department of Molecular Signaling, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Yamanashi, Japan
| | - Takahiko Mitsui
- Department of Urology, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Yamanashi, Japan
| | - Tatsuya Ihara
- Department of Urology, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Yamanashi, Japan
| | - Norifumi Sawada
- Department of Urology, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Yamanashi, Japan
| | - Manabu Kamiyama
- Department of Urology, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Yamanashi, Japan
| | - Jianglin Fan
- Department of Molecular Pathology, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Yamanashi, Japan
| | - Masayuki Takeda
- Department of Urology, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Yamanashi, Japan
| |
Collapse
|
31
|
Aoki T, Zakoji H, Kamiyama M, Yamagishi T, Takahashi N, Ootake Y, Kira S, Miyamoto T, Sawada N, Takeda M. [INTRAVESICAL MIGRATION OF A HEM-O-LOK CLIP AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY: A CASE REPORT]. Nihon Hinyokika Gakkai Zasshi 2016; 107:111-114. [PMID: 28442669 DOI: 10.5980/jpnjurol.107.111] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
The Hem-o-lok clips (HOLC) is frequently used for hemostasis of the lateral pedicles in robot-assisted prostatectomy (RARP) and laparoscopic radical prostatectomy (LRP). We report a rare post-operative complication, the migration of a HOLC into the bladder leading to calculus formation after RARP. A 54 year-old man underwent RARP with nerve- sparing procedure with HOLCs in the left neurovascular bundle. Three months later, he was referred to our hospital for pollakisuria and spontaneous hematuria. Abdominal ultrasonographic examination and computed tomography (CT) demonstrated a bladder stone that was 7 mm in diameter. On cystourethroscopy, he was noted to have a yellow-colored stone at 9 o'clock position of vesicourethral anastomosis. A cystolithotripsy for a bladder stone was performed until the surface of it was broken. A HOLC with a calculus was revealed and retrieved by stone forceps through the urethra. Since then, Intravesical migration of a HOLC has not been observed.
Collapse
Affiliation(s)
- Tadashi Aoki
- Department of Urology, Faculty of Medicine, University of Yamanashi
| | - Hidenori Zakoji
- Department of Urology, Faculty of Medicine, University of Yamanashi
| | - Manabu Kamiyama
- Department of Urology, Faculty of Medicine, University of Yamanashi
| | | | | | - Yuko Ootake
- Department of Urology, Faculty of Medicine, University of Yamanashi
| | - Satoru Kira
- Department of Urology, Faculty of Medicine, University of Yamanashi
| | - Tatsuya Miyamoto
- Department of Urology, Faculty of Medicine, University of Yamanashi
| | - Norifumi Sawada
- Department of Urology, Faculty of Medicine, University of Yamanashi
| | - Masayuki Takeda
- Department of Urology, Faculty of Medicine, University of Yamanashi
| |
Collapse
|
32
|
Locatelli F, Choukroun G, Fliser D, Moecks J, Wiggenhauser A, Gupta A, Swinkels DW, Lin V, Guss C, Pratt R, Carrilho P, Martins AR, Alves M, Mateus A, Gusmao L, Parreira L, Assuncao J, Rodrigues I, Stamopoulos D, Mpakirtzi N, Afentakis N, Grapsa E, Zitt E, Sturm G, Kronenberg F, Neyer U, Knoll F, Lhotta K, Weiss G, Robinson BM, Larkina M, Bieber B, Kleophas W, Li Y, Locatelli F, McCullough K, Nolen JG, Port FK, Pisoni RL, Kalicki RM, Uehlinger DE, Ogawa C, Kanda F, Tomosugi N, Maeda T, Kuji T, Fujikawa T, Shino M, Shibata K, Kaneda T, Nishihara M, Satta H, Kawata SI, Koguchi N, Tamura K, Hirawa N, Toya Y, Umemura S, Chanliau J, Martin H, Stamatelou K, Gonzalez-Tabares L, Manamley N, Farouk M, Addison J, Donck J, Schneider A, Gutjahr-Lengsfeld L, Ritz E, Scharnagl H, Gelbrich G, Pilz S, Macdougall IC, Wanner C, Drechsler C, Kuntsevich V, Charen E, Kobena D, Sheth N, Siktel H, Levin NW, Winchester JF, Kotanko P, Kaysen G, Kuragano T, Kida A, Yahiro M, Nanami M, Nagasawa Y, Hasuike Y, Nakanishi T, Stamopoulos D, Mpakirtzi N, Dimitratou V, Griveas I, Lianos E, Grapsa E, Sasaki Y, Yamazaki S, Fujita K, Kurasawa M, Yorozu K, Shimonaka Y, Suzuki N, Yamamoto M, Zwiech R, Szczepa ska J, Bruzda-Zwiech A, Rao A, Gilg J, Caskey F, Kirkpantur A, Balci MM, Turkvatan A, Afsar B, Alkis M, Mandiroglu F, Kim YO, Yoon SA, Kim YS, Choi SJ, Min JW, Cheong MA, Hasuike Y, Kida A, Oue M, Yamamoto K, Kimura T, Fukao W, Yahiro M, Kaibe S, Nanami M, Nakanishi T, Djuric PS, Ikonomovski J, Tosic J, Jankovic A, Majster Z, Stankovic Popovic V, Dimkovic N, Aicardi Spalloni V, Del Vecchio L, Longhi S, Violo L, La Milia V, Pontoriero G, Locatelli F, Shino M, Kuji T, Fujikawa T, Toya Y, Umemura S, Macdougall I, Rumjon A, Mangahis E, Goldstein L, Ryzlewicz T, Becker F, Kilgallon W, Fukasawa M, Otake Y, Yamagishi T, Kamiyama M, Kobayashi H, Takeda M, Toida T, Sato Y, Fujimoto S. DIALYSIS ANAEMIA. Nephrol Dial Transplant 2014. [DOI: 10.1093/ndt/gfu176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
33
|
Liu J, Liu J, Liu Y, Xu Y, Zhao X, Qian J, Sun B, Xing C, Kanda R, Hamada C, Nakano T, Wakabayashi K, Io H, Horikoshi S, Tomino Y, Ishimatsu N, Miyamoto T, Morimoto H, Nakamata J, Baba R, Kanegae K, Serino R, Kabashima N, Otsuji Y, Doi Y, Tamura M, Nakamata J, Morimoto H, Baba R, Ishimatsu N, Miyamoto T, Kanegae K, Serino R, Kabashima N, Otsuji Y, Doi Y, Tamura M, Kusumoto T, Fukami K, Yamagishi SI, Ueda S, Kaida Y, Hazama T, Nakayama Y, Ando R, Obara N, Okuda S, Tamura M, Matsumoto M, Miyamoto T, Kanegae K, Furuno Y, Serino R, Kabashima N, Otsuji Y, Bang-Gee H, Mazzotta L, Rosati A, Carlini A, Henriques VT, Zangiacomi Martinez E, Divino-Filho JC, Pecoits-Filho R, Cardeal Da Costa JA, Henriques VT, Henriques VT, Gama Axelsson T, Lindholm B, Carrero JJ, Heimburger O, Stenvinkel P, Qureshi AR, Akazawa M, Uno T, Kanda E, Maeda Y, Aktsiali M, Aktsiali M, Antonopoulou S, Tsiolaki K, Bakirtzi N, Patrinou A, Georgopoulou M, Liaveri P, Afentakis N, Tsirpanlis G, Hasegawa T, Nishiwaki H, Hirose M, Komukai D, Tayama H, Koiwa F, Yoshimura A, Lui SL, Lui S, Yung S, Tang C, Ng F, Lo WK, Chan TM, Koo HM, Doh FM, Yoo DE, Oh HJ, Yoo TH, Choi KH, Kang SW, Han DS, Han SH, Fernandes N, Fernandes N, Bastos MG, Gianotti Franco MR, Chaoubah A, Gloria Lima MD, Pecoits-Filho R, Divino-Filho JC, Qureshi AR, Kang S, Do J, Cho K, Park J, Yoon K, Chen JB, Cheng BC, Chen TC, Su YJ, Wu CH, Park Y, Jeon J, Tsikeloudi M, Pateinakis P, Patsatsi K, Manou E, Sotiriadis D, Tsakiris D, Teixeira L, Rodrigues A, Carvalho MJ, Cabrita A, Mendonca D, Kang S, Do J, Park J, Cho K, Yoon K, Bruschi M, Candiano G, Santucci L, Luzio S, Cannavo R, Ghiggeri GM, Verrina E, Varadarajan Y, Raju B, Cho KH, Do J, Kang S, Park JW, Yoon KW, Kim TW, Kimmel M, Braun N, Latus J, Alscher MD, Struijk D, Van Esch S, Krediet RT, Fernandes N, Van den Beukel T, Hoekstra T, Tirapani L, De Andrade Bastos K, Pecoits-Filho R, Qureshi AR, Bastos M, Dekker F, Divino-Filho JC, Yasuhisa T, Kanai H, Harada K, Kawai Y, Sugiyama H, Ito Y, Tsuruya K, Yoshida H, Maruyama H, Goto S, Nakayama M, Nakamoto H, Morinaga H, Matsuo S, Makino H, DI Gioia MC, Gallar P, Laso N, Rodriguez I, Cobo G, Oliet A, Hynostroza J, Herrero JC, Mon C, Ortiz M, Vigil A, Tomo T, Portoles J, Uta S, Uta S, Tato AM, Lopez-Sanchez P, Rivera M, Rodriguez-Pena R, Del Peso G, Ortega M, Felipe C, Tsampikaki E, Aperis G, Kaikis A, Paliouras C, Karvouniaris N, Maragaki M, Alivanis P, Kortus-Gotze B, Hoferhusch T, Hoyer J, Martino F, Kaushik M, Rodighiero MP, Creapldi C, Ronco C, Lacquaniti A, Lacquaniti A, Donato V, Fazio MR, Lucisano S, Cernaro V, Lupica R, Buemi M, Aloisi C, Uno T, Akazawa M, Kanda E, Maeda Y, Bavbek Ruzgaresen N, Secilmis S, Yilmaz H, Akcay A, Duranay M, Akalin N, Akalin N, Altiparmak MR, Trabulus S, Yalin AS, Ataman R, Serdengecti K, Schneider K, Bator B, Niko B, Braun N, Peter F, Ulmer C, Joerg L, Martin K, Dagmar B, German O, Fabian R, Juergen D, Stephan S, Dominik A, Latus J, Latus J, Ulmer C, Fritz P, Rettenmaier B, Hirschburger S, Segerer S, Biegger D, Lang T, Ott G, Kimmel M, Alscher MD, Braun N, Habib M, Korte M, Hagen M, Dor F, Betjes M, Habib M, Hagen M, Korte M, Zietse R, Dor F, Betjes M, Latus J, Latus J, Ulmer C, Fritz P, Rettenmaier B, Biegger D, Lang T, Ott G, Scharpf C, Kimmel M, Alscher MD, Braun N, Habib M, Korte M, Zietse R, Betjes M, Chang TI, Shin DH, Oh HJ, Kang SW, Han DS, Yoo TH, Han SH, Choi HY, Lee YK, Kim BS, Han SH, Yoo TH, Park HC, Lee HY, Horimoto N, Tuji K, Kitamura S, Sugiyama H, Makino H, Isshiki R, Isshiki R, Iwagami M, Tsutsumi D, Mochida Y, Ishioka K, Oka M, Maesato K, Moriya H, Ohtake T, Hidaka S, Kobayashi S, Higuchi C, Tanihata Y, Ishii M, Sugimoto H, Sato N, Kyono A, Ogawa T, Nishimura H, Otsuka K, Cho KH, Do JY, Kang S, Park JW, Yoon KW, Kim TW, Du Halgouet C, Latifa A, Anne Sophie V, Emmanuel D, Christine R, Francois V, Grzelak T, Czyzewska-Majchrzak L, Kramkowska M, Witmanowski H, Czyzewska K, Janda K, Krzanowski M, Dumnicka P, Sulowicz W, Rroji M, Seferi S, Barbullushi M, Likaj E, Petrela E, Thereska N, Cabiddu G, Dessi E, Arceri A, Laura P, Manca E, Conti M, Cao R, Pani A, Liao CT, Vega Vega O, Mendoza de la Garza A, Correa-Rotter R, Ueda A, Nagai K, Morimoto M, Hirayama A, Owada S, Tonozuka Y, Saito C, Saito C, Yamagata K, Matsuda A, Tayama Y, Ogawa T, Iwanaga M, Noiri C, Hatano M, Kiba T, Kanozawa K, Katou H, Hasegawa H, Mitarai T, Ros-Ruiz S, Ros-Ruiz S, Fuentes-Sanchez L, Jironda-Gallegos C, Gutierrez-Vilches E, Garcia-Frias P, Hernandez-Marrero D, Kang S, Lee S, Cho K, Park J, Yoon K, Do J, Lai X, Chen W, Guo Z, Braide M, Cristina V, Popa SG, Maria M, Eugen M, Martino F, DI Loreto P, DI Loreto P, Ronco C, Rroji M, Seferi S, Barbullushi M, Petrela E, Spahia N, Likaj E, Thereska N, Sanchez Macias LO, Sanchez Macias LO, Lares Castellanos KI, Hernandez Pacheco JA, Vega Vega O, Correa Rotter R, Pedro Ventura A, Olivia S, Teixeira L, Joana V, Francisco F, Maria Joao C, Antonio C, Rodrigues AS, Atas N, Erten Y, Erten Y, Onec K, Inal S, Topal S, Akyel A, Celik B, Okyay GU, Tavil Y, Zeiler M, Monteburini T, Agostinelli RM, Marinelli R, Santarelli S, Erten Y, Erten Y, Inal S, Onec K, Atas N, Okyay GU, Yaylaci C, Sahin G, Tavil Y, Guz G, Sindel S, Pinho A, Cabrita A, Malho Guedes A, Fragoso A, Carreira H, Pinto I, Bernardo I, Leao P, Janda K, Janda K, Krzanowski M, Kusnierz-Cabala B, Dumnicka P, Krasniak A, Chowaniec E, Tabor-Ciepiela B, Sulowicz W, Turkmen K, Ozbek O, Kayrak M, Samur C, Guler I, Tonbul HZ, Rusai K, Herzog R, Kratochwill K, Kuster L, Aufricht C, Meier CM, Fliser D, Schilling MK, Klingele M, Fukasawa M, Fukasawa M, Takeda M, Kamiyama M, Song YR, Kim HJ, Kim SG, Kim JK, Noh JW, Lee YK, Yoon JW, Koo JR. Peritoneal dialysis. Nephrol Dial Transplant 2012. [DOI: 10.1093/ndt/gfs243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Usui N, Kamiyama M, Tani G, Fukuzawa M. Prenatal differential diagnosis of congenital chloride diarrhea: the importance of a dilated fluid-filled rectum. Eur J Pediatr Surg 2011; 21:193-4. [PMID: 21283961 DOI: 10.1055/s-0031-1271637] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- N Usui
- Department of Pediatric Surgery, Osaka University Graduate School of Medicine, Suita, Japan.
| | | | | | | |
Collapse
|
35
|
Abstract
INTRODUCTION The mechanisms responsible for postoperative chylothorax in Congenital Diaphragmatic Hernia (CDH) patients remain unclear. The aim of the present study was to examine the clinical features of CDH that may contribute to an association with postoperative chylothorax. MATERIAL AND METHODS 198 neonates with CDH, in whom surgical repair of a diaphragmatic defect was performed between 1981 and 2008, were retrospectively studied. The patients were divided into 2 groups; patients with postoperative chylothorax (group I, n=11) and patients without postoperative chylothorax (group II, n=187). The clinical findings were compared between group I and group II to investigate potential predictive parameters for an association with chylothorax. Moreover, the clinical findings and treatments were evaluated in patients with chylothorax. RESULTS 11 of the 198 infants (5.5%) developed a chylothorax. Although the incidence of a prenatal diagnosis was slightly higher in group I, no relationship with other clinical features was found which would indicate the severity of CDH or the occurrence of postoperative chylothorax. Treatment for chylothorax was drainage alone in 2 cases, total parenteral nutrition with drainage in 8 infants and additional intrathoracic OK-432 infusion in 1 patient. No patients required surgical intervention for chylothorax. No recurrences were observed in this patient series. CONCLUSIONS It was concluded that postoperative chylothorax is not rare in infants after CDH repair. However, no statistically significant predictive parameters for chylothorax were identified, except for the presence of a prenatal diagnosis.
Collapse
Affiliation(s)
- M Kamiyama
- Osaka University Graduate School of Medicine, Department of Pediatric Surgery, Suita, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Inuzuka H, Zakohji H, Miyamoto T, Kira S, Kudo S, Kamiyama M, Sawada S, Tsuchida T, Fukazawa M, Araki I, Takeda M. V1698 OPERATIVE DIFFICULT POINTS IN THE LAPAROSCOPIC ADRENALECTOMY FOR GIANT PHEOCHROMOCYTOMA: COMPARISON BETWEEN RIGHT AND LEFT SIDES. J Urol 2010. [DOI: 10.1016/j.juro.2010.02.1544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
37
|
Zakoji H, Miyamoto T, Kamiyama M, Inuzuka H, Tsuchida T, Araki I, Takeda M. [Two cases of infants with acute renal failure due to bilateral obstructive ureteral stones associated with rotavirus gastroenteritis]. Nihon Hinyokika Gakkai Zasshi 2010; 101:29-33. [PMID: 20158076 DOI: 10.5980/jpnjurol.101.29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
We report on 2 infants with acute renal failure caused by bilateral obstructive ureteral stones associated with rotavirus gastroenteritis. A 28-month boy and a 13-month boy with several days history of watery diarrhea and vomiting were referred to our hospital because of anuria. They were diagnosed acute post-renal failure due to obstructive bilateral ureteral stones based on the findings of ultrasound scan and computed tomography. Immediately, percutaneous nephrostomy tubes were inserted for urinary drainage, serum levels of creatinine and uric acid returned to normal within several days. Sandy stones were excreted through the nephrostomy tubes with urine after urinary alkalization, which were proved to be mainly ammonium acid urate. Ammonium acid urate is rare in developed countries, but some cases of bilateral urolithiasis causing acute renal failure in infants with rotavirus gastroenteritis were reported in recent years. It has been known that the cause of acute renal failure is renal azotemia resulting from sustained hypovolemia, but post-renal causes due to ammonium acid urate stones should be taken into consideration.
Collapse
Affiliation(s)
- Hidenori Zakoji
- Department of Urology, Faculty of Medicine, University of Yamanashi
| | | | | | | | | | | | | |
Collapse
|
38
|
Senzaki H, Kamiyama M, Masutani S, Ishido H, Taketazu M, Kobayashi T, Katogi T, Kyo S. Efficacy and safety of torasemide in children with heart failure. Arch Dis Child 2008; 93:768-71. [PMID: 18337280 DOI: 10.1136/adc.2007.129239] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVE To examine the efficacy and safety of torasemide in children with chronic heart failure (HF). METHODS 102 children with chronic HF who had received oral torasemide were analysed. Of these, 62 (de novo group) were newly diagnosed as having HF and were given torasemide as a diuretic. The remaining 40 (replacement group) had been given furosemide for >3 months before the study, and furosemide was then replaced with torasemide. Clinical signs and symptoms of HF (assessed as the HF index), humoral factors and serum potassium concentrations before torasemide treatment were compared with those obtained 3-4 weeks after torasemide treatment. Patients were also monitored for adverse effects. RESULTS In the de novo group, torasemide significantly improved the HF index with concomitant improvement in plasma brain natriuretic peptide concentration (median (interquartile range) 52 (51) vs 43 (49) pg/ml). In a randomly selected group of 25 de novo patients with ventricular septal defect, echocardiography showed that torasemide significantly improved left ventricular geometry and function. In the replacement group, brain natriuretic peptide concentrations were also significantly decreased from 50 (104) to 45 (71) pg/ml after substitution of torasemide, but the HF index showed only a tendency for improvement (p = 0.07). Torasemide also had a potassium-sparing effect (de novo group, no change in potassium concentration; replacement group, significant increase from 4.2 (0.5) to 4.3 (0.5) mEq/l), and caused a significant rise in serum aldosterone concentration, consistent with the anti-aldosterone effect of this drug. Serum concentrations of sodium and uric acid had not changed after torasemide treatment, and there were no serious adverse events that necessitated drug withdrawal. CONCLUSION Torasemide can be safely used, and appears to be effective for treatment of HF in children. Future clinical trials are warranted to verify the present results.
Collapse
Affiliation(s)
- H Senzaki
- Department of Pediatric Cardiology and Cardiovascular Surgery, Saitama Medical University, Saitama, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Abstract
Computer simulations of complement titre measurement in sera by linearizing the sigmoidal curve of complement dose response were performed, to simplify the logarithmic calculations of CH50 values. CH50 titres of large variety of human sera including healthy donors and immune deficiency patients were estimated. The values obtained were compared with the hand-simulated results using the Y/(1-Y) conversion table and a log-log graphic paper. Using computer simulation, CH50 can be determined with great ease.
Collapse
Affiliation(s)
- M Kamiyama
- Blood Research Institute, St. Michael's Medical Center, Newark, NJ 07102
| | | | | |
Collapse
|
40
|
Maniwa A, Kamiyama M, Mikami Y, Furuya Y, Zakoji H, Tsuchida T, Nomura T, Fukazawa M, Takihana Y, Araki I, Takeda M. EFFICACY AND SAFETY OF PACLITAXEL AND GEMCITABINE COMBINATION AS THE CHEMOTHERAPY FOR ADVANCED/METASTATIC UROTHELIAL CANCER IN A SINGLE CENTER IN JAPAN. J Urol 2008. [DOI: 10.1016/s0022-5347(08)60340-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
41
|
Furuya Y, Araki I, Kamiyama M, Zakoji H, Takihana Y, Takeda M. Decreased expression of G protein-coupled receptor kinases in the detrusor smooth muscle of human urinary bladder with outlet obstruction. Int J Urol 2006; 13:1226-32. [PMID: 16984558 DOI: 10.1111/j.1442-2042.2006.01497.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
AIM We examine the expression of mRNA of G protein-coupled receptor kinase (GRK) subtypes and muscarinic acetylcholine receptor (M) subtypes in the detrusor smooth muscle of the human urinary bladder. Furthermore, we confirm the presence and the localization of GRK proteins in the detrusor smooth muscle of the obstructed bladder in comparison with the control bladder. METHODS Detrusor smooth muscle tissues of the human urinary bladder were obtained from 12 male patients; 6 patients did not have bladder outlet obstruction, and the other 6 patients had bladder outlet obstruction. Portions of the dome or anterior wall of the urinary bladder were used for the present study. Reverse transcription/polymerase chain reaction for GRK2, M2 and M3 was performed using total RNA extracted from human urinary bladder detrusor. Antibodies to GRK2, GRK3 and GRK4 were used to confirm the presence of the protein product in the human urinary bladder using immunohistochemical staining and the western blotting technique. RESULTS All complementary DNA (cDNA) transcribed from three different mRNA (M2, M3 and GRK2) were successfully amplified and size-fractionated. The expression of GRK2 protein was strong in the human bladder detrusor, but was significantly weakened by western blotting in obstructed bladder in comparison with control bladder. CONCLUSIONS Failure in desensitization mechanisms of muscarinic acetylcholine receptors might be related to storage symptom elicited by overactivity in obstructed bladder with benign prostatic hyperplasia.
Collapse
Affiliation(s)
- Yasuhisa Furuya
- Department of Urology, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Yamanashi, Japan.
| | | | | | | | | | | |
Collapse
|
42
|
Kamiyama M, Pozzi A, Yang L, DeBusk LM, Breyer RM, Lin PC. EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival. Oncogene 2006; 25:7019-28. [PMID: 16732324 DOI: 10.1038/sj.onc.1209694] [Citation(s) in RCA: 99] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Prostaglandin E2 (PGE2), a major cyclooxygenase (COX) metabolite, plays important roles in tumor biology. We studied the role of EP2, a receptor for PGE2, in tumor angiogenesis using EP2 knockout mice. We found that deletion of the EP2 receptor impaired tumor angiogenesis and this finding was confirmed by an in vivo corneal angiogenesis model and an ex vivo aortic ring assay. To further characterize the cellular mechanisms of the EP2 receptor in angiogenesis, we isolated primary pulmonary endothelial cells (ECs) from wild-type (wt) and EP2-/- mice and observed that EP2-/- ECs exhibited defects in vascular branch formation when compared to wt ECs. In addition, EP2-/- ECs showed impaired cell motility on collagen-coated surface and they responded poorly to PGE2-induced cell migration compared to control cells. However, no difference in cell proliferation was observed between the EP2-/- and wt Ecs. In addition, EP2-/- ECs were more susceptible to apoptosis than wt cells under growth factor depletion conditions. Collectively, our data demonstrate that EP2 signaling in endothelium directly regulates tumor angiogenesis by contributing to cell survival and endothelial cell motility. Moreover, our finding suggests that EP2 is a major receptor in PGE2-mediated cell motility in ECs.
Collapse
Affiliation(s)
- M Kamiyama
- Department of Radiation Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA
| | | | | | | | | | | |
Collapse
|
43
|
Sato S, Kamiyama M, Iwata T, Makita N, Furukawa H, Ikeda H. Moderate increase of mean daily temperature adversely affects fruit set of Lycopersicon esculentum by disrupting specific physiological processes in male reproductive development. Ann Bot 2006; 97:731-8. [PMID: 16497700 PMCID: PMC2803419 DOI: 10.1093/aob/mcl037] [Citation(s) in RCA: 117] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
BACKGROUND AND AIMS Global warming is gaining significance as a threat to natural and managed ecosystems since temperature is one of the major environmental factors affecting plant productivity. Hence, the effects of moderate temperature increase on the growth and development of the tomato plant (Lycopersicon esculentum) were investigated. METHODS Plants were grown at 32/26 degrees C as a moderately elevated temperature stress (METS) treatment or at 28/22 degrees C (day/night temperatures) as a control with natural light conditions. Vegetative growth and reproductive development as well as sugar content and metabolism, proline content and translocation in the androecium were investigated. KEY RESULTS METS did not cause a significant change in biomass, the number of flowers, or the number of pollen grains produced, but there was a significant decrease in the number of fruit set, pollen viability and the number of pollen grains released. Glucose and fructose contents in the androecium (i.e. all stamens from one flower) were generally higher in the control than METS, but sucrose was higher in METS. Coincidently, the mRNA transcript abundance of acid invertase in the androecium was decreased by METS. Proline contents in the androecium were almost the same in the control and METS, while the mRNA transcript level of proline transporter 1, which expresses specifically at the surface of microspores, was significantly decreased by METS. CONCLUSIONS The research indicated that failure of tomato fruit set under a moderately increased temperature above optimal is due to the disruption of sugar metabolism and proline translocation during the narrow window of male reproductive development.
Collapse
Affiliation(s)
- S Sato
- Faculty of Horticulture, Chiba University, 648 Matsudo, Matsudo City, Chiba 271-8510, Japan.
| | | | | | | | | | | |
Collapse
|
44
|
Komuro M, Kamiyama M, Furuya Y, Takihana Y, Araki I, Takeda M. Gene and protein expression profiles of prostaglandin E2 receptor subtypes in the human corpus cavernosum. Int J Impot Res 2005; 18:275-81. [PMID: 16239896 DOI: 10.1038/sj.ijir.3901408] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Prostaglandin E1 leads to penile erection, mainly via prostaglandin E2 (EP) receptors. This study aimed to identify the expression profile of EP receptor genes in human corpus cavernosum. Using the quantitative real-time reverse transcription polymerase chain reaction, the mRNA levels of EP receptor subtypes were measured. In addition, expressions of EP receptor subtype proteins were determined by immunohistochemical method. Among the four subtypes, EP4 receptor mRNA expression was the highest, and EP2 receptor mRNA followed, whereas EP1 and EP3 receptor mRNAs were hardly observed. Expression level of EP4 receptor mRNA was significantly higher than that of EP2 receptor mRNA. Expression of both EP2 and EP4 receptor proteins were clearly detected in the cavernous smooth muscle. These results may suggest that EP4 receptor plays an important role among four EP receptor subtypes for relaxation of smooth muscle in the human corpus cavernosum.
Collapse
Affiliation(s)
- M Komuro
- Department of Urology, University of Yamanashi, Faculty of Medicine, Yamanashi, Japan.
| | | | | | | | | | | |
Collapse
|
45
|
Araki I, Du S, Kamiyama M, Mikami Y, Matsushita K, Komuro M, Furuya Y, Takeda M. Overexpression of epithelial sodium channels in epithelium of human urinary bladder with outlet obstruction. Urology 2004; 64:1255-60. [PMID: 15596218 DOI: 10.1016/j.urology.2004.06.064] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2004] [Revised: 06/25/2004] [Accepted: 06/25/2004] [Indexed: 11/20/2022]
Abstract
OBJECTIVES To examine whether the epithelial sodium channel (ENaC) is expressed in the human urinary bladder and how its expression changes in association with outlet obstruction. Detrusor instability occurs in association with bladder outlet obstruction. The increase of afferent activity is one of the possible mechanisms for this detrusor instability. The ENaC expressed in mammals has been implicated in various mechanosensory functions. METHODS Specimens of urinary bladder mucosa were obtained from 9 controls and 9 patients with bladder outlet obstruction verified by the International Prostate Symptom Score, prostate volume, and urodynamic tests. In 7 patients with outlet obstruction, involuntary detrusor contraction was demonstrated. The expression and localization of ENaC proteins was examined using immunofluorescent staining. The quantification of ENaC gene expression was assessed by real-time reverse transcriptase-polymerase chain reaction. RESULTS The alpha-ENaC, beta-ENaC, and gamma-ENaC proteins were expressed in human urinary bladder epithelium with outlet obstruction, and the alpha-ENaC and gamma-ENaC proteins were virtually unstained in the control bladders. Alpha-ENaC, beta-ENaC, and gamma-ENaC mRNA were detected in 1, 6, and 4 of 9 control bladders, respectively. Each ENaC mRNA was clearly present in all obstructed bladders. The expression levels of each subunit in the obstructed bladders were significantly greater than those in controls. The quantified ENaC expression correlated significantly with the storage symptom score. CONCLUSIONS The ENaC expressed in the bladder epithelium might be implicated in the mechanosensory transduction in the bladder afferent pathways, thereby inducing detrusor instability by outlet obstruction.
Collapse
Affiliation(s)
- Isao Araki
- Department of Urology, University of Yamanashi, Interdisciplinary Graduate School of Medicine and Engineering, Tamaho, Yamanashi, Japan
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Komuro M, Kamiyama M, Furuya Y, Takihana Y, Araki I, Tanabe N, Takeda M. 1639: Prostaglandin E2 Receptor Gene Expression Profile in Human Corpus Cavernosum. J Urol 2004. [DOI: 10.1016/s0022-5347(18)38847-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
47
|
Araki I, Du S, Kamiyama M, Mikami Y, Takihana Y, Takeda M. 1730: Overexpression of Epithelial Sodium Channels in the Epithelium of Human Urinary Bladder with Outlet Obstruction. J Urol 2004. [DOI: 10.1016/s0022-5347(18)38922-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
48
|
Fukasawa M, Sakamoto H, Nagashima H, Kira S, Sawada N, Kamiyama M, Zakouji H, Nomura T, Araki I, Takeda M. Blood access intervention therapy using Gadoteridol for a patient with iodine allergy. ACTA ACUST UNITED AC 2004. [DOI: 10.4009/jsdt.37.1617] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
49
|
Abstract
Lower urinary tract symptoms (LUTS) are associated with lower urinary tract dysfunction. Symptoms are the subjective indicator of a disease or change in condition as perceived by the patient, caregiver, or partner and may lead the individual to seek help from health care professionals. LUTS are usually qualitative and, therefore, cannot usually be used to make a definitive diagnosis. LUTS also can indicate pathologies other than lower urinary tract dysfunction, such as urinary infection. LUTS are divided into 7 groups: storage, voiding (obstructive), postmicturition symptoms and 4 others. Voiding symptoms, which are caused by lower urinary tract obstruction, include slow stream, splitting or spraying, intermittency, hesitancy, straining, and terminal dribble. Postmicturition symptoms, which are experienced immediately after micturition, consist of the feeling of incomplete emptying and postmicturition dribble. Postmicturition dribble describes the involuntary loss of urine immediately after the individual has finished passing urine; in men, usually after leaving the toilet and in women, after rising from the toilet. Hence, postmicturition dribble is elicited by different situations or is considered as having different implications. For example, although postmicturition dribble usually implies incomplete emptying (voiding symptoms) in elderly men with benign prostatic hyperplasia, postmicturition dribble is often considered as urinary incontinence (a storage symptom) in many patients, even with bladder outlet obstruction. In such cases, detailed history taking and further evaluation, such as urinary flowmetry, postvoid residual volume, and comprehensive urodynamic evaluation, should be performed as appropriate. If no urodynamic abnormalities of either the detrusor or the outlet can be detected despite significant LUTS, factors unrelated to the lower urinary tract may be responsible for the voiding symptoms.
Collapse
Affiliation(s)
- Masayuki Takeda
- Department of Urology, University of Yamanashi, Faculty of Medicine, Yamanashi, Japan.
| | | | | | | | | | | |
Collapse
|
50
|
Fukasawa M, Matsushita K, Kamiyama M, Mikami Y, Araki I, Yamagata Z, Takeda M. The methylentetrahydrofolate reductase C677T point mutation is a risk factor for vascular access thrombosis in hemodialysis patients. Am J Kidney Dis 2003; 41:637-42. [PMID: 12612987 DOI: 10.1053/ajkd.2003.50125] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
BACKGROUND Many reports indicate that a high homocysteine (Hcy) level is a potential risk factor for such thrombotic diseases as arteriosclerosis, myocardial infarction, and cerebral infarction in healthy individuals or hemodialysis (HD) patients. The methylentetrahydrofolate reductase (MTHFR) C677T polymorphism has been reported to be closely related to plasma Hcy level. METHODS Using a cross-sectional design in this study, the relationship between arteriovenous fistula (AVF) obstruction and the MTHFR C677T point mutation was examined in 337 HD patients. RESULTS Results of multivariate analysis showed no significant influence of age, HD therapy duration, sex, or the presence of diabetes mellitus, cerebral infarction, or myocardial infarction. Only the presence of the MTHFR C677T polymorphism yielded a significant difference. Percentages of patients who experienced AVF obstruction were as follows: CC (12.6%), CT (20.3%), and TT (31.8%). The number of those who experienced obstruction was significantly larger with the TT than CC (P < 0.01). Moreover, total obstruction episode ratios were as follows: CC, 1 in 107.21 episodes/patient-month; CT, 1 in 74.08 episodes/patient-month; and TT, 1 in 50.33 episodes/patient-month. Episode percentages tended to be greater when the degree of mutation was greater, and a significant difference was observed between the CC and TT alleles (P < 0.01). CONCLUSION Although AVF obstruction is affected by numerous factors, there was a strong relationship between MTHFR C677T mutation and AVF obstruction. These findings suggest that the MTHFR C677T point mutation could serve as an important indicator in identifying susceptibility to AVF obstruction.
Collapse
Affiliation(s)
- Mizuya Fukasawa
- Department of Urology and Faculty of Medicine, University of Yamanashi, Japan.
| | | | | | | | | | | | | |
Collapse
|